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ABSTRACT 
 
Charles E. Miller: Improving Brain Slice Methodology 
(Under the direction of Dr. R. Mark Wightman) 
Brain slices are an in vitro preparation used to simplify the complexity of the brain by 
isolating particular regions of interest.  Dopamine neurons have been found to function 
differently under current brain slice protocols than in vivo.  To improve the worth of the 
information gained from brain slice experiments, it must be determined which elements of 
the in vivo environment are important to normal function.   Making these determinations is 
central to this dissertation.  Carbon-fiber microelectrodes were used to monitor electrically 
stimulated dopamine release in brain slices with fast-scan cyclic voltammetry (FSCV).  The 
first question asked is what role extracellular dopamine tone plays in controlling dopamine 
release.   Basal dopamine tone in vivo stimulates D2 autoreceptors, which regulate 
dopamine release; however, in brain slices, there is no dopamine tone.  Therefore, 
determining proper autoreceptor activation is important to making release biologically 
relevant.  Second, neurons fire action potentials along their axons to cause release at their 
terminals.   In brain slice experiments stimulation occurs at the nerve terminals.  To 
stimulate at the axons requires visualization of the dopamine neurons.  Two transgenic 
mouse models that make dopaminergic cells visible due to their fluorescence are evaluated.  
Lastly, electrochemical and immunohistochemical methods are used to account for 
norepinephrine and serotonin in these brain slices.  D2 autoreceptor stimulation, proper 
electrode placement, and the appropriate electrochemical approach are found to be 
important for improving current brain slice methodology. 
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Chapter 1 
Electrochemistry in Brain Slices 
Introduction 
The brain is the most complex and least understood organ of the body.  Although 
much has been learned, there is still no overall theory that describes brain function to guide 
research.  There are many reasons to pursue an understanding of the brain.  There are a 
number of diseases/disorders that have eluded description and cures, such as Alzheimer’s, 
Parkinson’s, Huntington’s, depression, schizophrenia, etc.  Additionally, the brain affects the 
entire body, so many of these diseases/disorders have wide-ranging physical symptoms.  
Psychologists and cognitive neuroscientists are interested in the mind-body connection.  
How do the firing of neurons and chemicals acting on receptors translate to behavior and 
thought?  Studying the actions of biogenic amines including dopamine, serotonin, and 
norepinephrine are central to understanding the brain.  The primary excitatory and inhibitory 
neurotransmitters are glutamate and γ–aminobutyric acid (GABA), respectively.  However, 
biogenic amines are neuromodulators, substances that change the neuronal response to 
neurotransmitters such as glutamate and GABA.  For example, dopamine inhibits glutamate 
release at its synapse with GABAergic cells in the striatum (Tang et al., 2001).  In other 
words, dopamine is modulating synaptic strength between the glutamatergic and GABAergic 
neurons.    
Neurons are electrically excitable cells in the nervous system that process and 
transmit information.  These cells contain ionic channels that are responsive to the voltage 
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across the cell’s plasma membrane.  The traffic of ions through these channels provides the 
electrical excitability that defines neurons and allows information to be transmitted from one 
end of the cell to the other.  A schematic of a neuron is shown in Figure 1.1.  A typical 
unipolar neuron receives inputs from other cells at the dendrites.  These inputs are summed 
in the cell body where action potentials are generated if the inputs provide a sufficient 
excitation.  An action potential is the wave-like propagation of membrane voltage changes 
down the axon to the terminals caused by the opening and closing of voltage gated ion 
channels (Figure 1.2).  When the action potential reaches the terminal, it causes the 
opening of calcium channels (Ca2+, Figure 1.3).  The influx of extracellular calcium initiates a 
cascade of events that results in the release of neurotransmitters (DA, for dopamine) from 
the neuron into the extracellular space.  The released contents can then diffuse across the 
synapse to act on post-synaptic receptors (D1 and D2), provide feedback to the releasing 
neuron through pre-synaptic autoreceptors (D2) and be taken up into the releasing neuron 
by membrane bound transporters (DAT) (Figure 1.3).   
A neuron exists within a network of neurons that form circuits, which constitute a 
subsystem of the brain.  It is the connections made by large numbers of neurons that allow 
them to store, process, and direct responses to information.  For example, the dopamine 
neurons are shown in Figure 1.4, by labeling tyrosine hydroxylase (TH).  Two major 
pathways are present in this panel (Zeiss, 2005).  The mesolimbic pathway consists of 
dopamine cell bodies in the ventral tegmental are (VTA) that project axons along the medial 
forebrain bundle (MFB) to terminate in the nucleus accumbens (Acb).  The nigrostriatal 
pathway consists of dopamine cell bodies in the substantia nigra compacta (SNc) that 
project axons along the MFB and terminate in the caudate putamen (CP).  The neurons of 
the nigrostriatal pathway are part of the basal ganglia motor loop (Hoover and Strick, 1999).   
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Figure 1.1. Schematic of a neuron.  Dendrites receive inputs, which are summed in the cell 
body.   If the inputs provide sufficient excitation, an action potential propagates to the 
terminals, where substances are released and can interact with other cells. 
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Figure 1.2. Action potential mechanism.  A.) 1.Upon depolarization of the plasma 
membrane, voltage-dependent sodium channels open allowing sodium to diffuse into the 
neuron along its concentration gradient. 2. As the neuron continues to depolarize, potassium 
channels open and diffuse out of the cell along its concentration gradient.  Adjacent sodium 
channels open, and immediate sodium channels close. 3. Sodium/potassium pumps re-
establish membrane resting potential as the action potential propagates.  B.) The membrane 
potential changes at a fixed position along the axon as an action potential passes. The 
corresponding changes in ion channel status that cause these potential changes are noted.  
Images at kvhs.nbed.nb.ca/gallant/biology/action_potential_propagation.html. 
A 
B 
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Figure 1.3.  Synaptic structure of a dopamine terminal. Dopamine (DA) is synthesized from 
tyrosine and packaged into vesicles by VMAT.  Upon stimulation by an action potential 
calcium channels (Ca2+) open, causing an influx of calcium that triggers vesicle fusion with 
the plasma membrane.  This fusion event causes release.  DA can then bind autoreceptors 
(D2) to inhibit release, post-synaptic receptors (D1 and D2) to transmit the signal, and the 
dopamine transporter (DAT) which takes DA up into the terminal. 
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Figure 1.4. TH labeling of the mouse brain visualizes two major dopamine pathways.  The 
nigrostriatal pathway includes the SNc, MFB, and CP.  The mesolimbic pathway includes 
the VTA, MFB, and Acb.  These regions are dark in the images.  To the left is a side-view of 
the dopamine neurons in a mouse brain.  The vertical line through this view indicates where 
a slice has been taken to produce the image shown on the right. A.) The line passes through 
the terminal region of these pathways.  In the image on the right heavy TH labeling can be 
seen in these large terminal regions.  B.) The line passes through the cell body region of 
these pathways.  In the image on the right, the VTA and SNc can be seen labeled for TH 
(Zeiss 2005). 
 
A 
B 
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Figure 1.5. The connections within the basal ganglia motor loop.  The DA nigrostriatal 
neurons from SNc to striatum (CP) are in red and provide both inhibitory and excitatory 
inputs based on the receptors expressed post-synaptically.  These neurons operate within a 
larger circuit of neurons with complex interconnectivity.  Image at 
www.mdvu.org/library/disease/pd/par_path.html. 
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A flow chart of the circuits that form the basal ganglia are shown in Figure 1.5.  The 
complexity of these circuits makes explaining a change in DA signaling in vivo difficult.  In 
vitro brain slice experiments isolate the neuron from the circuits and systems to investigate 
the properties of the neuron that regulate its activity.  In our lab, we can measure the activity 
of pre-synaptic mechanisms that control the amount of neurotransmitter released, such as 
feedback from autoreceptors and uptake by transporters.  
Brain slices 
The mammalian brain can be described in reference to three axes (Figure 1.6a).  Dorsal-
ventral describes the axis from the top of the brain to the bottom.  Lateral-medial describes 
the axis from the sides of the brain inward to the center.  Anterior-posterior is the axis from 
the front of the brain backward. Likewise, brain slices can be made along these three axes 
(Figure 1.6b).  The experiments in this thesis involve coronal and horizontal brain slices.  
Coronal slices are made along the lateral-medial axis at different distances from bregma, a 
point of reference on the skull used to measure anterior-posterior distances in the brain.  
Horizontal slices are made along the anterior-posterior axis at different depths from dura, a 
membrane covering the top of the brain.  Referring to the dopamine pathways described 
above, coronal slices of the striatum would sever dopamine nerve terminals from the rest of 
the neuron.  Since this slice isolates dopamine terminals, it is commonly used to investigate 
presynaptic mechanisms that control extracellular concentrations of dopamine.  A horizontal 
brain slice taken from the correct depth can include the complete mesolimbic pathway.  
Since most of a dopamine neuron is present within this slice, the cell can be stimulated at 
different locations and release and uptake can be investigated at different recording sites 
throughout the slice. 
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Figure 1.6.  Anatomical axes and slice orientations.  A.) Three anatomical axes are shown 
within the context of the human central nervous system.  These axes apply within the mouse 
brain as well.  B.) These axes are redrawn for comparison to the three brain slice 
orientations that are taken along these axes.  Coronal slices contain the medial-lateral axis 
and are taken at different anterior-posterior positions.  Horizontal slices encompass the 
anterior-posterior axis and are taken at different dorsal-ventral positions.  Sagittal slices are 
run along the anterior-posterior axis and are taken at different lateral-medial positions.   
A 
B 
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Figure 1.7.   Brain slice samples in a tissue chamber (Warner Instruments).  A.) Superfusion 
buffer is used to sustain the sample and administer pharmacological agents.  Prior to the 
tissue chamber an in-line heater maintains buffer temperature (not shown).  A microscope is 
used to aid placement of the stimulating electrode and microelectrode with 
micromanipulators.  With the use of a Xenon lamp source and the appropriate filters, 
fluorescence from samples can be viewed.  For example, fluorescence from green 
fluorescent protein (GFP) is observed in many samples throughout the thesis. B.) The GFP 
filter spectral characteristics and the GFP spectra. 
A 
B 
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To slice the brain, the extracted brain is mounted in a vibratome (World Precision 
Instruments, Sarasota, FL, USA) according to the orientation desired.  The brain is then 
sliced to a desired thickness (200-300 µm) and placed in a tissue chamber (Figure 1.7).  
The brain slice is kept functional by a superfusion of buffer.  If brain tissue is sliced to thickly, 
then nutrients within the buffer will not reach interior cells as nutrients are consumed by cells 
closer to the surface of the slice.  The brain slice thickness used provides the structural 
robustness necessary to withstand sustained manipulation.   Under these conditions, slices 
can remain viable 8-10 hours.  This highlights additional benefits of using brain slices.  The 
environment is controlled by the experimenter such that temperature and buffer 
composition, including pharmacological agents, can be finely controlled.  Additionally, the 
system has an overhead microscope to aid precise electrode placement with 
micromanipulators.  Other spectroscopic microscopy methods can be used as well, including 
fluorescence and infrared imaging.   
Measurement 
The bulk of what is known about brain function has been discovered by electrophysiologists, 
who use electrodes to measure the changes in voltage that indicate the “firing” of action 
potentials.  The action potential was first described in 1952 by Hodgkin and Huxley using the 
squid axon.  Since that time it has been found that much of the information conveyed in the 
brain is encoded in the frequency of neuron firing (Heine et al., 2008).  Which neurons fire is 
controlled by the molecules being released from firing neurons and the distribution of 
corresponding receptors on target neurons.  To study the concentration and time course of 
these release events most investigators have used two primary techniques: microdialysis 
and electrochemistry. 
12 
 
Microdialysis is a technique for sampling the extracellular brain fluid using a probe 
with a semi-permeable membrane (Watson et al., 2006).  The fluid can be analyzed off-line, 
typically with high-pressure liquid chromatography (HPLC).  This approach allows one to 
monitor changes of many extracellular components simultaneously and with high sensitivity.  
However, microdialysis is relatively slow (collections times of several minutes) and the probe 
is large (200-400 µm wide) relative to electrodes (<10 µm wide).   
The electrochemical approach used in this work is fast-scan cyclic voltammetry 
(FSCV).  The temporal resolution of this technique allows collection rates of 10-60 Hz to be 
used.  Carbon-fiber microelectrodes (CFME’s) used here are 25 µm long and 5-7 µm in 
diameter (Figure 1.8) and are made as described previously (Kawagoe et al., 1993).  To the 
electrode a triangle waveform is applied. Figure 1.9 shows the waveform used for detecting 
dopamine in this work.  In the absence of analyte, the high scan rate generates a large 
background current caused by capacitive charging and oxidation of surface groups.  Over 
short time intervals, this background is stable and can be subtracted from the signal when 
the analyte is present.  Dopamine adsorbs to the electrode at the holding potential, oxidized 
on the forward scan, and reduced on the return scan.  The resulting cyclic voltammogram 
identifies the analyte and measures the concentration present, following a calibration of the 
electrode.  A similar approach is used to detect serotonin.  Serotonin can be detected with 
the same waveform as dopamine but will lead to electrode fouling.  A modified waveform 
that avoids fouling is shown in Figure 1.10.  The portion of the waveform at more negative 
potentials than the holding potential serves to clean the electrode surface.  The very fast 
scan rate is used to out-run side reactions that serotonin oxidation products undergo. 
While FSCV with CFME’s provides spatial and temporal resolution superior to 
microdialysis, it is more limited in selectivity and sensitivity.  Only electroactive substances  
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. An SEM image of a cylinder carbon-fiber microelectrode.  The carbon fiber is 
encapsulated in a pulled glass capillary to form a seal less than 10 µm in diameter.  The 
portion of the fiber extending from the seal is cut to a length about 25 µm (Kawagoe et al., 
1993).   
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Figure 1.9.   DA detection.  A.)  The triangle waveform used to detect DA.  B.)  The 
oxidation-reduction reaction of dopamine that causes the faradaic current measured. C.) 
The background current generated by applying the waveform to the microelectrode.  D.)  
The current obtained in the presence of dopamine.  E.) The background subtracted cyclic 
voltammogram of dopamine. 
C 
A 
B 
D 
E 
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Figure 1.10.   5-HT detection.  A.)  The triangle waveform used to detect 5-HT.  B.)  The 
oxidation-reduction reaction of 5-HT that causes the faradaic current measured. C.) The 
background subtracted cyclic voltammogram of 5-HT . 
 
 
 
C 
A 
B 
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can be detected with FSCV, while offline analysis with microdialysis allows one to analyze 
many neurochemicals.  Moreover, FSCV is limited in the number of analytes that can be 
simulataneously measured.  Generally, the potential window is so small that it is best when 
only one analyte is monitored at a time, but newer data analysis approaches, such as 
principle component regression, are improving the resolution of multi-component signals 
(Heien et al., 2005).   
Additionally, FSCV is sensitive to changes in the surface of the microelectrode that 
affect the response to an analyte.   This includes fouling which reduces electrode sensitivity, 
but also includes substances that increase electrode sensitivity.  Quinpirole and 
quinelorane, commonly used pharmacological agents, increase the microelectrodes 
response to dopamine.  Using flow-injection analysis (FIA) to analyze electrode sensitivity to 
a bolus of 2 µM dopamine, it was found that quinpirole increases electrode sensitivity to 
dopamine despite the fact that quinpirole is not electroactive itself.  This increase in 
sensitivity is blocked by coating the electrode in Nafion, a cation exchange membrane.  
Quinpirole increase the signal by 120 +6% of control with a bare electrode, but a Nafion- 
coated electrode’s sensitivity does not change with the presence of quinpirole (98 +2%).  
Quinelorane, an analog of quinpirole, also increases the sensitivity to the same bolus (118 
+5%, Figure 1.12).  While it is not known at this time what the mechanism of this change in 
sensitivity is, it may be that Nafion is blocking adsorption of quinepirole/quinelorane to the 
surface of the electrode or preventing it from changing the double layer structure near the 
electrode. 
While microdialysis can look at slow changes in the extracellular concentration of 
brain fluid components, FSCV is sufficiently fast (millisecond temporal resolution) to 
investigate the components of a release event.  Shown in Figure 1.13 is the typical release  
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Figure 1.11.   In a flow-cell apparatus, a bolus of dopamine was injected in the presence 
and absence of quinpirole.  A.) Quinpirole enhances a bare electrode’s current response to 
dopamine, although quinpirole itself is not electroactive. B.) This enhancement of sensitivity 
is absent when the electrode is coated with Nafion, the perfluorinated sulfonate polymer 
shown on the right.   
Nafion-coated Electrode
Bare Electrode
A 
B 
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Figure 1.12.   Effect of quinpirole and quinelorane on DA sensitivity.  In a flow-cell 
apparatus, a bolus of dopamine was injected in the presence and absence of quinpirole and 
quinelorane.  Quinpirole increases a bare electrode’s sensitivity to dopamine (120 +6% of 
control) but does not increase a Nafion-coated electrode’s sensitivity to dopamine (98 +2% 
of control).  There is a significant difference in the increase in sensitivity to dopamine in the 
presence of quinpirole between Nafion-coated and bare electrodes (n = 5, p < 0.02).  
Quinelorane, an analog of quinpirole, increases a bare electrode’s sensitivity to dopamine 
by a similar amount (118 +5% of control).   
 
 
 
19 
 
 
 
 
 
Figure 1.13.   Representative trace of stimulated release in the CP of a mouse brain slice.  
Single-pulse stimulation applied at the time indicated by the arrow.  The concentration of 
extracellular dopamine increases immediately upon stimulation.  This increase indicates the 
release of dopamine from the terminals.  The concentration decreases more slowly and is 
due to the uptake by DAT as DA is cleared from the extracellular space. 
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profile elicited by a single current pulse stimulation in a brain slice.  This profile contains a 
rapidly increasing segment indicating release followed by a slower descending component 
indicating clearance of the substance.  The signal is on the second time scale that can be 
best measured by electrochemical approaches. 
Pre-synaptic controls 
Neurons synthesize biogenic amines, package them into vesicles, and release them to the 
extracellular space upon stimulation. The release of dopamine from neurons is very similar 
to that of the other biogenic amines (Cooper et al., 2003) and is briefly described here (see 
Figure 1.3).  Dopamine is synthesized from the amino acid tyrosine.  TH, the rate-limiting 
enzyme in catecholamine synthesis, converts tyrosine to dihydroxyphenylalanine (L-DOPA).  
L-DOPA is then converted to dopamine by aromatic amino acid decarboxylase (AADC).  
Dopamine is then packaged into vesicles by the vesicular monoamine transporter (VMAT).  
When an action potential reaches a nerve terminal, it causes the opening of voltage-gated 
calcium channels and a large influx of extracellular calcium.  There are a number of calcium 
sensitive proteins both on the surface of vesicles and the inner surface of the plasma 
membrane.  They respond to the influx of extracellular calcium by fusing the vesicle with the 
plasma membrane, thus causing dopamine within the vesicle to be released to the 
extracellular space.  There are several pharmacological points of control in this process.  
One can inhibit TH, VMAT, and calcium channels.  One could remove calcium from the 
extracellular buffer being superfused.  One could also remove sodium or use a sodium 
channel blocker, such as tetrodotoxin (TTX), to inhibit the initiation of action potentials. 
The D2-autoreceptor is a receptor found on dopaminergic terminals that provide 
negative feedback to the cell (Figure 1.3).  It is a metabotropic receptor, which means it is 
coupled to G-proteins that serve as second messengers within the cell.  Substances that 
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bind to a receptor and activate it are called an agonist.  Dopamine, quinpirole, and 
quinelorane are D2-receptor agonists.  When these agonists bind the autoreceptor, they 
activate a second messenger system that targets several points in the cell to lower the 
amount of dopamine.  First, it leads to the phosphorylation of TH, which reduces the rate of 
dopamine synthesis (Wolf et al., 1986).  Second, it leads to the phosphorylation of GIRK 
channels (G protein activated inward rectifying potassium channels) (Einhorn et al., 1991).  
By increasing potassium conductance, the terminal membrane potential is made less 
positive and thus lowering the probability of opening sodium and calcium channels, i.e. 
lowering the chance and magnitude of release. 
Once dopamine is released, it can return to the interior of the neuron by being taken 
up by the dopamine transporter (DAT).  DAT uptake is driven by the sodium gradient across 
the plasma membrane.  Two sodium ions are transported into the cell with each molecule of 
dopamine.  One chloride ion is transported in as well to avoid a charge buildup.  Since 
dopamine is being measured on the outside of the neuron, its uptake causes a 
disappearance of signal and is primarily responsible for the descending portion of the trace 
in Figure 1.13.  The rate of uptake can be modeled using Michaelis-Menton kinetics  
(Wightman et al., 1988; Kawagoe et al., 1992; Jones et al., 1995). Thus, the presumed 
scheme is (Matthews and Holde, 1996): 
(DA)o + T ↔ (DA)T → (DA)I + T 
where (DA)o is extracellular dopamine, (DA)i is intracellular dopamine, and T is the 
dopamine transporter.  DA binds the transporter, which then changes conformation to 
expose DA to the inside of the cell, and DA dissociates from the transporter.  The Michaelis–
Menten rate equation for dopamine uptake may be written as: 
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d[DA]/dt = [DA]p – Vmax/(KM/[DA] + 1) 
where [DA] is the brain extracellular concentration of dopamine and [DA]p is the change in 
concentration of dopamine at the electrode produced by each stimulus pulse.  Vmax is the 
maximal rate of uptake, which is dependent on DAT concentration.  KM is the concentration 
of DA at which the rate of uptake is half of Vmax.    
The kinetics of uptake by DAT can be slowed by adding an uptake inhibitor, such as 
cocaine, methamphetamine, or nomifensine.  This change in kinetics can be understood as 
that of a competitive inhibitor, which competes with the endogenous ligand to bind the 
protein.  In this case, the uptake inhibitors bind DAT and thus interfere with DA uptake.  In 
the presence of a competitive inhibitor (I), the additional equilibrium must be considered: 
I + T ↔ IT 
Under this paradigm (KM)app, the apparent KM, is defined as KM(1 + [I]/Ki), where Ki is the 
dissociation constant for the above reaction, and is defined as Ki = [I][T]/[IT].  Therefore, the 
introduction of an uptake inhibitor will increase the apparent KM, thus increasing the time DA 
persists in the extracellular space (Figure 1.14). 
 
Animals 
The experiments described here are conducted in mice.  Therefore, conclusions from this 
data provide information useful in basic research on rodents and are not extendable to other 
species, including humans, although some similarities may exist.  Rodents are commonly 
used in brain research.  They have a highly evolved mammalian brain but are still simple 
enough for necessary in vitro experiments, such as brain slice experiments.  While many 
different types of rodents are used in brain research, including rats and guinea pigs, mice  
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Figure 1.14.   Representative trace of uptake inhibition after incubation with 30 µM cocaine.  
Single-pulse stimulation applied at the time indicated by the arrow.  Application of cocaine 
increases the time needed for DAT to clear DA from the extracellular space.  Since cocaine 
competitively binds to DAT, the kinetics of DA clearance are slowed. 
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were used here because many transgenic models exist that aid brain slice experiments.  
Specifically, GFP transgenic mice are used in this work.  They express green fluorescent 
protein (GFP) in their dopaminergic neurons (Kessler et al., 2003).  Due to their intrinsic 
fluorescence, dopaminergic neurons are easily identified in a brain slice and aid electrode 
placement.  They have been generated on a C57BL/6 background strain, which is referred 
to as wild-type (WT) mice throughout this thesis.  This is a strain of mouse that has been 
used in the Wightman lab since 1998 (Jones et al., 1998).  The C57BL/6 is the most widely 
used inbred strain, and in fact, was the DNA source for the sequencing of the mouse 
genome (Jackson Laboratory, www.jax.org).  Adults are used to ensure the cessation of cell 
migration and rapid change inherent to development of the mature brain.  Males have been 
used to simplify controls.  Female mice could be used, but one must account for any effect 
of their estrous cycle.  Gender studies have shown that female mice release more dopamine 
and have greater uptake (Walker et al., 2000).  The species, strain, and gender are all 
relevant variables that are controlled for throughout these experiments and provide the 
context for the interpretation of results. 
Thesis Overview 
The action of D2-autoreceptor agonists quinpirole and quinelorane to alter the short-term 
inhibition provided by the autoreceptor is investigated in Chapter 2.  Then, the visualization 
of dopaminergic cells by fluorescent techniques using transgenic mice, specifically PLAP 
and GFP transgenic mice, are explored in Chapter 3.  These GFP and WT mice are 
compared in terms of dopamine release, calcium sensitivity, dopamine tissue content, rates 
of uptake and cocaine inhibition in Chapter 4.  Then, the GFP transgenic mice are used in 
Chapter 5 to develop remote stimulation, in which axons within horizontal slices of the 
mesolimbic pathway are stimulated in order to elicit release some distance away at the 
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terminals.  The development of an electrochemical approach to determine the concentration 
of serotonin and dopamine in mixed solutions and in brain regions where mixed signals are 
measured is discussed in Chapter 6.   
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Chapter 2 
Dynamics of Short-term Inhibition with D2 Agonists 
Introduction 
How do tonic levels of dopamine effect the short-term dynamics of stimulated 
dopamine release?  The normal, tonic firing of dopamine neurons provides a background of 
slowly changing (minutes scale) dopamine concentrations maintained in the extracellular 
space which provide tonic activation of dopamine receptors (Grace, 1991).  In a coronal 
brain slice there is no dopamine tone.  This has been proven by the lack of change in 
dopamine release elicited by a one-pulse stimulation upon addition of a D2-receptor 
antagonist to the slice buffer (Kennedy et al., 1992).  The lack of tone should have 
consequences on dopamine release dynamics.  Differences in dopamine release measured 
in brain slices and in vivo have been reported.  For example, in the intact brain the amount 
of dopamine released per stimulation pulse, [DA]p, remains constant  during stimulation of 
the medial forebrain bundle (May et al., 1988), while it decreases rapidly in vitro (Kennedy et 
al., 1992).   
In brain slices, it has been shown that stimulated release of dopamine activates  D2-
autoreceptors that inhibit subsequent stimulated release (Kennedy et al., 1992; Phillips et 
al., 2002).  In awake-behaving rats as well as anesthetized rats it has been shown that the 
amount of dopamine released for a given stimulation is dependent upon the history of 
stimulation (Montague et al., 2004).  Short-term factors controlling dopamine release 
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dynamics are mediated by D2-autoreceptors (Kita et al., 2007).  While it is impractical to 
remove dopamine tone in vivo, the in vitro setting provides an opportunity to monitor how 
these short-term dynamics change as the D2-autoreceptors become tonically activated.     
Unfortunately dopamine cannot be added to the buffer to provide this tone.  First, it is 
the target analyte and could complicate measurements of dopamine release.  Moreover if 
dopamine is applied to a brain slice, it is cleared from the extracellular space by a high-
affinity uptake system and packed into vesicles.  This could increase the amount of release 
but will not result in tonic activation of the autoreceptors.  In the intact brain, dopamine tone 
is accomplished by asynchronous firing of dopamine neurons (Venton et al., 2003).  
However an electrical stimulation of the brain slice will cause synchronous release.  To 
provide the tone desired, a D2-autoreceptor agonist that is not electrochemically active is 
preferred.  In this work, quinpirole and quinelorane are used to investigate changes in short-
term inhibition under a paired-pulse paradigm. 
Materials and methods 
Chemicals 
(-)-Quinpirole hydrochloride, quinelorane dihydrochloride, and 2-Ethoxy-1-ethoxycarbonyl-
1,2-dihydroquinoline (EEDQ) was obtained from Sigma-Aldrich (St Louis, MO, USA). For 
administration of quinpirole and quinelorane to brain slices, 10 mM stock solutions were 
prepared by dissolving the appropriate weight into a known volume of deionized water.  For 
dose-response curves, serial dilutions of the greatest concentration were used.  EEDQ or 
vehicle were injected i.p. 24 hours prior to sacrifice and brain slicing. 
Animals 
Animals were handled in accordance with protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina. C57/BL6 (wild-type) mice were 
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obtained from The Jackson Laboratory (Bar Harbor,ME, USA) at 5–6 weeks of age. Upon 
receipt, mice were housed at the University of North Carolina Animal Husbandry Facility in 
Kerr Hall. Mice were provided food and water ad libitum and were kept under conditions of 
controlled temperature, humidity, and a 12-h light/dark cycle. 
Brain slices 
Mice were deeply anesthetized by ether inhalation and decapitated.  The brain was 
immediately removed and placed in ice-cold aCSF.  The aCSF solution consisted of (in 
mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, D-
glucose 11. The pH was adjusted to 7.4 with 5 M NaOH and the buffer was continuously 
saturated with 95% O2/5% CO2. The cerebellum was sliced off with a razor blade and the 
brain was mounted on a Teflon block using Krazy Glue ®. Brain slices were made using an 
NVSL vibratome (World Precision Instruments, Sarasota, FL, USA). Coronal slices 
containing the striatum were made 300-µm thick, obtained at +0.3 to +1.3 mm from bregma.  
Brain slices were stored in ice-cold aCSF. A single slice was submerged under aCSF 
maintained at 34°C and continuously flowing (2 mL/min) through a superfusion chamber 
(Warner Instruments, Hamden, CT, USA).  Each brain slice was equilibrated for 30 min prior 
to obtaining measurements. To expose the brain slice to a given drug, the appropriate 
volume of drug stock solution was added to the buffer reserve and introduced by a peristaltic 
pump to the slice through a threeway valve. A cumulative dosing regimen was used to 
collect concentration-response data. Brain slices were allowed to equilibrate for 30 min at a 
given drug concentration prior to exposing the slice to the next higher concentration. 
Electrochemistry 
Carbon-fiber cylinder microelectrodes were made as previously described (Kawagoe et al., 
1993) using T650 carbon fibers (Amoco, Greenville, SC, USA) cut to a length of 25 µm.  
Electrodes were epoxied (Miller-Stevenson, Danbury, CT, USA) to ensure a good seal, and 
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dipped immediately in acetone for a few seconds to remove residual epoxy from the carbon 
fiber.  A triangular waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -
0.4 V, was applied to the carbon-fiber working electrode, versus a Ag/AgCl reference 
electrode, at a scan rate of 600 V/s.  An update rate of 10 Hz was used for all experiments 
except the quinelorane dose-response for which a 60 Hz update rate was used.   
The carbon fiber was inserted until the tip was 60-70 µm below the surface of the 
brain slice in the dorsolateral caudate region of the striatum between the prongs of a bipolar 
stimulating electrode (FHC, Bowdoinham, ME, USA), situated 200 µm apart. To evoke 
dopamine release, a single biphasic stimulating current pulse (2 ms each phase, 350 µA in 
amplitude) was applied to the stimulating electrode. The current arising from dopamine 
oxidation (at about 0.6 V) in successive voltammograms was measured and plotted versus 
time.  
Statistics 
The peak current arising from dopamine oxidation in response to each stimulation was 
adjusted with a correction factor to account for the change in sensitivity upon the 
introduction of quinpirole and quinelorane, see Chapter 1.  This current is expressed as a 
percentage of the value obtained before drug application. Data were considered significant 
at the 95% confidence level and are reported as the mean ± SEM for n animals.  Statistical 
significance was evaluated using an unpaired t-test. Dose-response curves were evaluated 
with non-linear regression to a sigmoidal dose-response curve (GraphPad Software Inc., 
San Diego, CA, USA).   
 
Results 
Short-term inhibition 
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Short-term inhibition is illustrated with FSCV measurements made during a 5 s stimulation 
pulse interval and a 30 s stimulation pulse interval (Figure 2.1).  The difference in peak 
height following stimulation can be expressed as a ratio of release due to the second 
stimulation pulse (S2) to the release due to the first stimulation pulse (S1).  At a short pulse 
interval, such as 5 s, there is much greater inhibition (S2/S1 = 0.42, Figure 2.1A) than at a 
longer pulse interval, such as 30 s (S2/S1 = 0.94, Figure 2.1B) under control conditions.  
Upon the addition of selective D2 agonist quinelorane the magnitude of S1 is reduced as 
expected.  Moreover, the S2/S1 ratio decreases for both pulse intervals, but the percentage 
decrease is much greater for the short pulse interval (40% of control) than the longer pulse 
interval (23% of control). 
Dose-Response curves 
Quinelorane and quinpirole inhibit dopamine release in a dose-dependent manner (Figure 
2.2).  Quinelorane (EC50 = 5.3 +11 nM) is a potent analog of quinpirole (EC50 = 40 +11 nM).  
The Hill slope is not significantly different for these two drugs (p > 0.05), presumably due to 
their similar modes of action.  The dashed line represents the presumptive curve for 
dopamine based on reported EC50 values (12 +12 nM). 
Dose-Response of Short-term Inhibition 
Quinpirole causes a decrease in the S2/S1 ratio for a 5 s pulse interval up to concentrations 
about its EC50 (Figure 2.3).  Moreover, there is no change for a 30 s pulse interval.  The 
difference between the 5 s and 30s pulse interval in percent change of the S2/S1 ratio is 
highly significant for several concentrations (25 nM p < 0.01, 50 nM and 100nM p < 0.005, 
Figure 2.3).  As the quinpirole concentrations increase further, the S2/S1 ratio returns to pre-
drug levels.   
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Figure 2.1.  Short‐term inhibition of dopamine release.  Representative traces of the brain slice 
response to paired‐pulse stimulations in the dorsal striatum at short and long pulse separations are 
shown with the change in magnitude upon addition of quinelorane.  Stimulations are indicated by 
the arrows and separated by the time noted between the arrows.  A)  The ratio of dopamine release 
elicited by a second stimulation pulse relative to the release elicited by the first stimulation pulse 
(S2/S1) is 0.42 for a 5s pulse separation and is further reduced by 40% with the addition of 10 nM 
quinelorane.  B) The  S2/S1 ratio is 0.94 under control conditions with a 30s pulse separation and is 
further reduced by 23% with the addition of 10 nM quinelorane.   
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Figure 2.2.  D2-autoreceptor mediated inhibition of release.  The peak current response for 
a single-pulse stimulation was measured as a function of D2-autoreceptor agonist 
concentration and normalized to the average response pre-drug.  Sigmoidal dose response 
curve fits are statistically similar for all parameters except the EC50.  Therefore, a 
hypothetical dopamine response curve was built using an EC50 of 12 +12 nM and a Hill 
slope of -1.7 +0.2. 
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Figure 2.3.  Quinpirole short-term inhibition dose response.  The change in the S2/S1 ratio 
with the cummative dosing of quinpirole is expressed relative to the pre-drug value.  There is 
no change in this ratio when using a 30 s pulse separation.  The change in response when 
using a 5 s pulse separation diverges from the 30 s response significantly at 25 nM (* p < 
0.01), 50 nM and 100nM (** p < 0.005). 
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The percent changes for a 5 s pulse interval are similar in pattern between the two 
agonists (Figure 2.4).  However, for quinelorane there is less difference between the percent  
changes with a short and long pulse interval.  This is due to the modest decrease in S2/S1 
ratio for the 30 s pulse interval.  In fact, there is a significant difference (p < 0.001) at 10 nM 
between quinelorane (87 +3%) and quinpirole (100 +1%).     
Dependence on Receptor Availability 
Injection of EEDQ (6 mg/kg, i.p.) 24 hours before a brain slice experiment reduces available 
D2 receptors by about 44% (Saller et al., 1989).  The result of reducing the fraction of 
available receptors is an increased lower plateau (p < 0.0001, Figure 2.5).  The changes in 
the S2/S1 ratio with increasing concentrations of quinpirole are similar with vehicle (1:2:1 
ratio of propylene glycol:water:ethanol) treatment as seen previously (Figure 2.6).  EEDQ 
treatment prevents the return of S2/S1 ratios to pre-drug levels (at 1 µM, p < 0.02).  The 
divergence in S2/S1 ratio between vehicle-treated mice and EEDQ-treated mice occurs at 
quinpirole concentrations above 500 nM, concentrations at which the bottom plateaus 
diverge.     
 
Discussion 
Short-term inhibition, expressed as an S2/S1 ratio, changes with D2-autoreceptor activation.  
This is true for two different agonists of differing potency and is likely true for dopamine.  
Although dopamine could not be used in these experiments, its potency has been reported 
in transfected cells (4-14 nM) and is between the potency of quinpirole and quinelorane 
(Bates et al., 1991; Mercier et al., 2001).  Therefore a dose-response curve for dopamine  
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Figure 2.4.  Quinelorane short-term inhibition dose response.  The change in the S2/S1 ratio 
with the cummative dosing of quinlorane is expressed relative to the pre-drug value.  The 
change in S2/S1 ratio when using a 5 s pulse separation diverges from the 30 s response 
significantly at 10 nM (*p < 0.01). 
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Figure 2.5.  EEDQ effect on quinpirole dose response.  The quinpirole dose response was 
evaluated in the dorsal striatum of mice injected with either vehicle or EEDQ (6 mg/kg, i.p.) 
24 hours prior to the experiment.  The bottom plateau is significantly increased in the EEDQ-
treated animal (* p< 0.0001).  The other paramers of the dose response to quinpirole are 
similar in vehicle-treated mice (EC50 = 57 +11 nM, Hill slope = -1.6 +0.1) and EEDQ-treated 
mice (EC50 = 48 +11 nM, Hill slope = -1.3 +0.1).   
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Figure 2.6.  EEDQ effect on quinpirole short-term inhibition dose response. The change in 
S2/S1 ratio diverges between vehicle-treated mice and EEDQ-treated mice above 500 nM 
quinpirole.  The S2/S1 ratio is significantly different at 1 µM (* p < 0.02).   
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would lie between the dose-response curves for those two agonists, displayed as a dash 
line in Figure 2.2. Furthermore, the changes in short-term inhibition measured can be 
assumed to occur for dopamine at concentrations intermediate to those measured for these 
agonists.   
Using a short pulse interval, the change in the S2/S1 ratio with agonist concentration 
is biphasic, a falling portion with an inflection about the EC50 of the agonist followed by a 
rising portion.  For a longer pulse interval, where short-term inhibition is much weaker, the 
agonists have much less effect on the S2/S1 ratio.  Although there appears to be very little 
short-term inhibition with a 30 s pulse interval under control conditions or in the presence of 
quinpirole, quinelorane increases the short-term inhibition at this long pulse interval.  This 
may be due to quinelorane’s greater potency.  Persistent activation of D2 receptors can lead 
to sensitization (Vortherms et al., 2006).  Sensitization would make the autoreceptor more 
responsive to the dopamine released upon the second stimulation thereby increasing short-
term inhibition.   
The initial decrease of short-term inhibition with a 5 s pulse interval can be 
understood as an additive effect of the dopamine released for S1 and the inhibitory action of 
the agonist.  It may also include some degree of sensitization.  There are three factors that 
may contribute to the return of the S2/S1 ratio to baseline.  First, S1 is growing smaller and 
therefore is having less of an inhibitory effect.  Second, the receptor occupancy is higher 
with an increasing quinpirole background, so the addition of a small amount of dopamine 
from S1 may not contribute significantly to the autoreceptor response.  Third, the 
autoreceptors are possibly being desensitized due to the high level of activation inherent to 
this experiment.  The first two factors can be addressed by reducing the receptor reserve 
with EEDQ. 
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 EEDQ chemically modifies the dopamine receptor irreversibly such that in can no 
longer bind either agonists or antagonists but without changing the dissociation constant 
(Kd) of the remaining receptors (Belleau et al., 1969; Kalsner, 1970).   Due to the reduction 
in available D2-autoreceptors,  the maximal inhibition is less with EEDQ treatment than with 
vehicle. The greater magnitude of S1 relative to vehicle at these high concentrations of 
quinpirole keeps the S2/S1 ratio low despite the increased receptor occupancy.  A rightward 
shift in the dose-response curve has been reported as an effect of EEDQ administration.  
This effect is found when measuring inhibition of forskolin-stimulated cAMP accumulation 
(Burris et al., 2002) and inhibition of forskolin-induced activation of tyrosine hydroxylase 
(Bohmaker et al., 1989).  Measuring changes in second messenger levels may be more 
sensitive to these perturbations than the cummulative cellular output of how much dopamine 
is released.  This shift has also been reported in the rat striatum by measuring the inhibition 
of tritiated dopamine release with apomorphine (Yokoo et al., 1988).   The release was 
elicited by 2 min, 1 Hz, unipolar (20 mA, 2 ms) electrical stimulations.  These stimulations 
are much more intense than the single-pulse stimulations used here.  The rightward shift 
may become apparent with greater dopamine release.  Since the EC50 did not change in our 
preparation, it indicates that there is a sufficient receptor reserve to respond to modest 
concentrations of agonist but at higher concentrations the receptors become saturated. 
 These results indicate that changes in tonic activation of D2-autoreceptors causes 
changes in the strength of short-term inhibition.  The concentrations over which these 
changes occur shift with the potency of the agonist, but the range remains about an order of 
magnitude.  Therefore a similar pattern would presumably emerge for dopamine, with a 
decrease followed by an increase in the S2/S1 ratio about its EC50.  Therefore, the dopamine 
concentrations enveloping the dynamic range in short-term inhibition would be between 2.4 
nM and 60 nM.  
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 There are many differences remaining between in vivo and brain slice preparations 
beyond autoreceptor tone that could impact the extension of these results to the intact 
animal.  For example, in the brain slice stimulation is local to the measurement which can 
cause the release of other substances that could interact with the dopamine terminal.  The 
concentration of dopamine release is much higher under control conditions in a brain slice 
than spontaneous release events in the intact animal.  The dopamine concentration of 
spontaneous release events in the caudate putamen are reported to be about 200nM 
(Robinson et al., 2002), yet the pre-drug concentrations of dopamine release in brain slices 
are about 1.5 µM.    With the appropriate caveats, these results show that changes in the 
tonic activation of autoreceptors are relevant to short-term dynamics of dopamine release. 
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Chapter 3 
Visualizing Dopaminergic Neurons in Transgenic Mice 
Introduction 
The mammalian brain is sufficiently complex and heterogeneous that placement of 
chemical sensors must be precise and specific so that appropriate interpretation of the 
measured responses can be made.  The identification of specific cell types within a brain 
slice would aid the placement of chemical sensors, such as microelectrodes.  For example, 
dopaminergic terminals are sparse in some regions of the brain including the prefrontal 
cortex, amygdala, and hippocampus.  Measuring dopamine release in these regions can be 
challenging due to the difficulty in placing microelectrodes sufficiently close to release sites.  
The localization of a fluorescent signal to a particular cell type would provide a target for 
sensor placement.  Traditional histological techniques are generally not useful in this 
application because they employ fixation or permeabilization of the tissue which sacrifices 
the viability of the sample.   
To aid in the visualization of dopaminergic neurons in mouse brain slices, two 
approaches have been investigated, both with transgenic mice.  The first involves labeling 
live tissue with fluorescently tagged antibodies to a transgenic marker that is expressed in 
specific cells.  The second approach involves the targeted expression of a fluorescent 
protein.  Cell specificity is accomplished the same way in each mouse type; the expression 
of the transgene is driven by the tyrosine hydroxylase (TH) promoter.  TH is specifically 
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expressed in catecholaminergic cells, so the transgenes will be expressed specifically as 
well.   
A line of transgenic mice were generated which express human placental alkaline 
phosphatase (PLAP) on the outer surface of the cell membrane of catecholaminergic cells 
(Gustincich et al., 1997).  An antibody specific to PLAP conjugated to a fluorescent dye has 
been used to localize a fluorescent signal to PLAP expressing cells in culture (Hochstetler et 
al., 2000).  In this chapter, the efficacy of using these mice and the antibody-dye conjugate 
for visualizing dopaminergic neurons in brain slices is explored. 
Another line of transgenic mice have since been generated that express enhanced 
green fluorescent protein (GFP) in catecholaminergic neurons (Kessler et al., 2003). Brain 
slices from these animals require no antibody labeling since they intrinsically fluoresce.  The 
use of these mice in identifying release sites in the central amygdaloid nucleus and ventral 
temental area (VTA) is explored.   
 
Materials and Methods 
Animals 
Animals were handled in accordance with protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina. A transgenic mouse line was 
used that express human placental alkaline phosphatase in catecholaminergic cells 
(Gustincich et al., 1997).  A transgenic mouse line in which catecholamine containing cells 
express the gene for the enhanced green fluorescent protein was used (Kessler et al., 
2003).  Upon receipt, mice were housed at the University of North Carolina Animal 
47 
 
Husbandry Facility in Kerr Hall. Mice were provided food and water ad libitum and were kept 
under conditions of controlled temperature, humidity, and a 12-h light/dark cycle. 
Brain slices 
Mice were deeply anesthetized by ether inhalation and decapitated.  The brain was 
immediately removed and placed in ice-cold aCSF.  The aCSF solution consisted of (in 
mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, D-
glucose 11. The pH was adjusted to 7.4 with 5 M NaOH and the buffer was continuously 
saturated with 95% O2/5% CO2. The cerebellum was sliced off with a razor blade and the 
brain was mounted on a Teflon block using Krazy Glue ®. Brain slices were made using an 
NVSL vibratome (World Precision Instruments, Sarasota, FL, USA). Coronal slices 
containing the striatum were made 300-µm thick, obtained at +0.5 to +1.0 mm from bregma.  
Coronal slices containing the substantia nigra and ventral tegmental area were obtained at -
2.8 to -3.3 mm from bregma.  For immunohistochemistry, the brain slices were made 200-
µm thick.  Brain slices were stored in ice-cold aCSF. A single slice was submerged under 
aCSF maintained at 34°C and continuously flowing (2 mL/min) through a superfusion 
chamber (Warner Instruments, Hamden, CT, USA).  Each brain slice was equilibrated for 30 
min prior to obtaining measurements.  
Labeling with PLAP Antibody 
The monoclonal PLAP antibody, E6, (De Waele et al., 1982) was conjugated to the Alexa 
Fluor ® 555 dye (Invitrogen, Carlsbad, CA) as previously described (Gustincich et al., 1997).  
The slices were incubated in a 35-mm culture plate with the antibody-dye conjugate (3 
µg/1mL of aCSF) for 15 minutes at 37° C in an incubator.  Then, the slice was placed in the 
tissue superfusion chamber, where the slice is rinsed with aCSF buffer and recovers for 30 
minutes before stimulating release.   
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Epifluorescent Microscopy 
To visualize the fluorescence in brain slices, an upright microscope (Nikon Eclipse E600FN, 
Melville, NY) was used with a xenon lamp source to excite fluorescence.  a Nikon G-2E/C 
bandpass filter set (filter 540/25 for excitation, 620/60 for emission, and a 565 LP dichroic 
mirror) was employed when viewing samples from PLAP mice,, and a Nikon endow GFP 
bandpass filter set (filter 470 CWL for excitation, 525 CWL for emission, and a 495 LP 
dichroic mirror) was employed when viewing samples from GFP mice.  A CCD camera 
(Photometrics Sensys, Tucson, Arizona) was used to capture images.  Photoshop was used 
to determine the relative fluorescence within a slice. 
Electrochemistry 
Carbon-fiber cylinder microelectrodes were made as previously described (Kawagoe et al., 
1993) using T650 carbon fibers (Amoco, Greenville, SC, USA) cut to a length of 25 µm.  
Electrodes were epoxied (Miller-Stevenson, Danbury, CT, USA) to ensure a good seal, and 
dipped immediately in acetone for a few seconds to remove residual epoxy from the carbon 
fiber.  A triangular waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -
0.4 V, was applied to the carbon-fiber working electrode, versus a Ag/AgCl reference 
electrode, at a scan rate of 600 V/s.  An update rate of 10 Hz was used for all experiments.   
The carbon fiber was inserted until the tip was 60-70 µm below the surface of the 
brain slice between the prongs of a bipolar stimulating electrode (FHC, Bowdoinham, ME, 
USA), situated 200 µm apart. To evoke dopamine release, a single biphasic stimulating 
current pulse (2 ms each phase, 350 µA in amplitude) was applied to the stimulating 
electrode. The current arising from dopamine or serotonin oxidation (at about 0.6 V) in 
successive voltammograms was measured and plotted versus time.  
49 
 
Immunohistochemistry 
Slices were fixed in 2% formaldehyde in Sorenson's buffer (0.15 m Na2HPO4/KH2PO4 at pH 
7.4) for 4 h. The slices were rinsed three times with 1X PBS (Tissue Culture Facility, Chapel 
Hill, NC, USA). Then, normal goat serum (NGS, Life Technologies, Rockville, MD, USA) was 
combined with 0.2% BSA/PBS solution (1 : 10, NGS : BSA/ PBS) containing 0.3% Triton-
100X.  The slices were incubated in this blocking solution for 2 h.  The Primary antibody 
solutions were incubated for overnight (15hours) at 4°C with slow agitation and rinsed with 
PBS.  For double labeling, secondary antibody was diluted 1:1000 and incubated overnight 
with the slices.  For PLAP/DAT or PLAP/TH double labeling experiments, the PLAP primary 
antibody-dye conjugate was simultaneously incubated with either the DAT or TH 
unconjugated primary antibody (Rabbit, Invitrogen).  Primary antibodies were diluted into 0.5 
mL of PBS and then 5 mL of blocking solution to final dilutions as follows: anti-DAT, 1:100; 
anti-TH, 1:100.  The secondary antibodies used wasAlexa Fluor ® 488 conjugated goat anti-
rabbit. Then, the slices were rinsed with PBS, placed on slides, and examined by confocal 
microscopy. 
Confocal microscopy 
Throughout this work, anatomical locations were determined by comparison with a mouse 
brain atlas (Paxinos and Franklin, 2004). The brain slices containing the desired regions 
were placed onto microscope slides with glass wells to maintain their structural integrity. Into 
these wells, Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA) was added. After the 
slices were placed in mounting medium, they were coverslipped, and sealed with clear nail 
varnish.  The confocal images were collected on a Leica SP2 Laser Scanning Confocal 
Microscope (Leica Microsystems, Confocal Microscopy, Germany) in the Michael Hooker 
Microscopy Facility at the University of North Carolina at Chapel Hill.  Photomultiplier tubes 
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were used to detect the fluorescence from the fluorochromes in the multiple-labeling 
experiments. 
 
Results 
Dopamine Release and Fluorescence in PLAP mice 
In brain slices fluorescently labeled with an antibody to PLAP, nerve terminal regions with 
high fluorescent intensity are expected to release more dopamine than areas of lower 
fluorescent intensity because the fluorescent intensity should be a direct index of terminal 
density.  This hypothesis was tested in the dorsal lateral caudate putamen of the PLAP 
mice.  The epifluorescent image shows the quality of labeling with this protocol (Figure 
3.1a).  It appears that there is some non-specific adsorption on the surface of the slice that 
becomes clearer when the epifluorescent image is compared to a confocal image of 
conventional immunohistochemical labeling with TH.  Confocal microscopy is widely used to 
allow one to focus below this top layer and capture images of specific labeling.  
Epifluorescence captures light from the entire specimen, including the surface of the slice.  
The rectangles indicate where the electrode was placed while stimulated release was 
measured.  The average current traces are shown for each position.  The magnitude of 
release was determined by the peak current in the cyclic voltammogram taken at the time 
when dopamine release has reached a maximal level following stimulation.  When the 
relative fluorescent intensity is compared to the oxidation current of dopamine, there is a 
weak linear relationship (r2 = 0.23, Figure 3.1c).  To determine why this might be true, the 
expression of PLAP and the efficacy of this labeling protocol were tested, as discussed 
below.  The mice were known to have the gene for PLAP from genotyping results (data not 
shown). 
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Figure 3.1.  Relationship between fluorescent intensity of PLAP labeling and dopamine 
release.  A) PLAP labeling of a live mouse brain slice containing the caudate putamen (CP). 
Squares indicate electrode location for the corresponding traces.  TH labeling of fixed tissue 
imaged by confocal microscopy to the right.  B) Single-pulse stimulated release at the 
positions indicated in the squares. C)  Linear regression of the relative fluorescence in the 
squares compared to the release at those positions (r2 = 0.23).  
 
A
CB
CP 
52 
 
PLAP Labeling 
To test the spatial specificity of PLAP expression, co-localization experiments were 
conducted with a membrane bound marker, the dopamine transporter (DAT), and a cystolic 
marker, tyrosine hydroxylase (TH).  As shown in Figure 3.2a the plasma membrane is 
clearly visualized by the fluorescence arising from the DAT antibody.  There is high co-
localization of TH and PLAP labeling in the same cell (Figure 3.2b).  However, the PLAP 
labeling does not overlay DAT labeling, but instead is found within the membrane.   
 PLAP labeling of fixed, permeabilized tissue was conducted in horizontal brain slices 
to determine the depth at which a slice could be prepared that contains a lengthy projection 
of axons to facilitate remote stimulation.  Figure 3.3 shows the labeling of an axon that 
arborizes in a terminal field of the nucleus accumbens.  One could place the working 
electrode among the terminals and the stimulating electrode along the axons.  The 
stimulating electrode would be placed some distance sufficient to elicit dopamine release 
but not stimulate the other cells local to those releasing terminals.  This slice was obtained 
by gluing the brain to the slicing block upside down, such that the dorsal surface is 
contacting the glue. 
PLAP Antibody Permeation 
For slices in which measuring release is a goal, incubation times with the antibody must be 
short to retain cell function.  To determine whether a tissue labeling protocol is viable with 
the short-time incubations, the depth of penetration of the antibody into the slice was 
examined after a 15 minute incubation.  Images of brain slices labeled with the PLAP 
antibody conjugate were taken with a confocal microscope and a side view was obtained.   
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Figure 3.2.   Cytoplasmic expression of PLAP.  A) DAT (cyan) and PLAP (yellow) labeling of 
the VTA,  B) TH (magenta) and PLAP (yellow) labeling of the VTA. 
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Figure 3.3.  PLAP labeling of a horizontal slice containing the mesolimbic pathway.  Axons 
from the medial forebrain bundle can be seen to arborize in the terminal field of the nucleus 
accumbens. 
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Figure 3.4.  An confocal images of xz profiles after a 15 min incubation of the brain slice in a 
solution containing the PLAP antibody.  The slice is not fixed or permeabilized. A) Striatum, 
B) VTA. 
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The resulting images were taken from a terminal rich region and a cell body region with 
similar results (Figure 3.4).  The bright thick line at the top indicates the surface of the slice 
and the degree of non-specific adsorption that occurs.  This presents a problem for 
epifluorescence as the surface obfuscates the view of the more specific labeling deeper in 
the slice.  In both brain regions, the fluorescence reaches a depth of approximately 50 µm.  
That may be the depth the antibody conjugate has diffused and labeled or it could be a limit 
on sampling depth due to scattering and absorption of light by the tissue.  In either case, the 
light used to direct electrode placement is coming from a depth shallower than the 60-70 µm 
that the electrodes are normally placed. 
Dopamine Release and Fluorescence in GFP mice 
Since visualizing dopaminergic cells in GFP mouse brain slices does not require a labeling 
step, there should be a stronger correlation between dopamine release and fluorescence.   
A brain region of sparse dopaminergic innervation, the amygdala, was used to more sharply 
resolve release sites (Figure 3.5a). The relationship between relative fluorescent intensity 
and current due to dopamine oxidation is linear (r2 = 0.999, Figure 3.5c).   
 Somatodendritic release was tested in the VTA.  Cells were easily identified due to 
their intense fluorescence; however, release was a similar magnitude throughout the VTA 
(Figure 3.6).  The most intense fluorescence and weakest release were measured at the cell 
bodies in the VTA.  The linear regression reveals little relationship between fluorescence 
and release (Figure 3.6c). 
Discussion 
The weak relationship of dopamine release and fluorescent intensity suggest that the PLAP 
labeling was not completely specific.  A fundamental assumption of the live tissue labeling 
approach is that the PLAP protein is being expressed on the surface of the cell where it is  
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Figure 3.5.  Relationship between fluorescent intensity and dopamine release in the central 
amygdaloid nucleus. A) Epifluorescent image of a GFP mouse brain slice containing the 
central amygdala.  To the right is a mouse brain atlas (braininfo.rprc.washington.edu), the 
yellow box indicates corresponding region.   Squares indicate electrode location for the 
corresponding traces. B) Stimulated release (24-pulse, 60 Hz) at the corresponding 
positions.  The orange squares indicate the end of the stimulation. C)  Linear regression of 
the relative fluorescence in the squares compared to the release at those positions (r2 = 
0.999).   
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Figure 3.6.  VTA Relationship between fluorescent intensity and dopamine release. A) 
Epifluorescent image of a GFP mouse brain slice containing the VTA. Squares indicate 
electrode location for the corresponding traces. To the right is a mouse brain 
atlas(braininfo.rprc.washington.edu), the yellow box indicates corresponding region.  B) 
Stimulated release (10-pulse, 60 Hz) at the corresponding positions.  The orange squares 
indicate the end of the stimulation. C)  The relative fluorescence in the squares compared to 
the release at those positions (r2 = 0.89).    
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accessible to the antibody.  If it were expressed within the cell, the antibody would be 
prevented from interacting with its target, unless the tissue is permeabilized as in Figure 3.3.  
However, permeabilized cell membranes prevent the study of release since the cells are no 
longer functionally viable.  If PLAP was being expressed on the surface as desired, then the 
labeling for PLAP and DAT, a surface protein, should overlay.  This is not the case but 
rather TH, a cytoplasmic protein, and PLAP labeling are co-localized.  These findings 
indicate that PLAP is not being expressed properly on the cell surface and would thus not be 
available for live tissue labeling.  This change in expression from early reports may be due 
to genetic drift.  Genetic drift is a stochastic process of change in allele frequencies.  Given 
sufficient breeding cycles, the expression of a non-native protein can be altered and even 
silenced (Hickman-Davis and Davis, 2006). 
A lack of sufficient tissue permeation by the labeled antibody was found with short 
incubation times.  When one conducts immunohistochemistry with fixed tissue, antibody 
incubation is performed on the order of hours.  The short incubation time is used here in the 
interest of keeping the tissue live and viable.  Longer incubation times were attempted, but 
the brain slice did not recover.  There may be ways to improve tissue survivability for longer 
incubations.  However, this is unnecessary thanks to the development of a mouse that 
makes visualization much less labor intensive.   
PLAP mice require the antibody to be harvested from hybridoma cells, then purified, 
conjugated to the dye, purified again, and screened for proper dye-to-protein ratio.  To 
visualize dopamine neurons in GFP mice requires only an excitation source and the proper 
filters.  The linear regression of dopamine release and GFP fluorescent intensity is very high 
at neuron terminals in the amygdala due to the specificity of gene expression.  This means 
the fluorescent signal in these mice can be reliably used to guide electrode placement in 
regions of low terminal density. 
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The visualization of cell bodies in the VTA provides the means to test the nature of 
somatodendritic release in dopamine neurons.  Release of a similar magnitude in all 
recording areas could be due to two possible explanations.  First, uptake may be sufficiently 
slow that dopamine diffuses from release sites and creates a uniform concentration 
throughout the recording area.  Second, most release may originate from the diffuse 
network of dendrites instead of the cell bodies.  In fact, the less intensely fluorescent areas 
adjacent to the cells in the VTA consist of a dense network of dendrites that do not fluoresce 
brightly due to their small diameter.  Since these less fluorescent regions is where release 
was the highest, it seems that release primarily occurs at the dendrites not the cell bodies 
The facile identification of dopamine neurons within brain slice preparations provides 
the opportunity to perform novel experiments.  One such experiment involves remote 
stimulation of release.  The working electrode is placed among nerve terminals to measure 
dopamine release in the standard fashion.  The stimulating electrode is placed some 
distance away along axons that project to the terminals from which release will be 
measured.  By arranging electrodes in this manner, one will specifically stimulate the 
dopamine neurons and not the other neighboring cell types.  This type of experiment is 
explored more fully in Chapter 5.  By extension, one could move the working electrode to 
the cell bodies in the VTA from which these axons project.  By stimulating the axons and 
measuring release at the cell bodies, one can study antidromic stimulation.  This will provide 
similar benefits of specificity over the VTA experiment in Figure 6.  Release from midbrain 
dopamine cells, using both local and antidromic stimulation, is explored more fully in 
Chapter 6.  In conclusion, GFP mice allow rapid identification of dopaminergic neurons and 
aid proper electrode placement. This facilitates making measurements in otherwise 
challenging regions of the brain, such as the amygdala, and in novel contexts, such as with 
remote stimulation. 
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Chapter 4 
Comparison of eGFP Transgenic Mice and their WT Background Strain 
Introduction 
The dopaminergic system within the mammalian brain has been widely studied due 
to its central role in a number of brain functions and disorders.  The mesocorticolimbic 
pathway includes cells of the ventral tegmental area (VTA) that project to the nucleus 
accumbens (NAc), amygdala, and frontal cortex.  This pathway is involved in emotion, 
reward, and memory processing (Jackson and Westlind-Danielsson, 1994; Schultz et al., 
1997; Phillips et al., 2004) and plays a role in disorders such as schizophrenia and drug 
addiction (Di Chiara and Imperato, 1988; Goldstein and Deutch, 1992).  The nigrostriatal 
pathway includes cells of the substantia nigra compacta (SNc) that project to the dorsal 
striatum.  This pathway is involved in motor control (Bradbury et al., 1985; Missale et al., 
1998; Sealfon, 2000) and plays a role in diseases such as Parkinson’s and Huntington’s 
disease (Bjorklund and Lindvall, 1984; Jakel and Maragos, 2000; Johnson et al., 2006).  The 
tuberoinfundibular pathway refers to dopamine neurons in the hypothalamus that project to 
the pituatary gland to regulate levels of prolactin in blood (Picetti et al., 1997) and plays a 
role in lactation and fertility (Civelli et al., 1993).  
The development of transgenic mice that express green fluorescent protein (GFP) in 
catecholaminergic cells has provided a new tool for studying these dopamine systems.  
Mice that express GFP under the regulation of the tyrosine hydroxylase (TH) promoter have 
been used to study TH regulation through development (Matsushita et al., 2002).  
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Fluorescent cells facilitate enrichment strategies prior to implantation, which is used as a 
strategy to alleviate disorders such as Parkinson’s disease (Sawamoto et al., 2001; 
Donaldson et al., 2005).  Cells can now be tracked during development and differentiation to 
provide more information on factors determining cell fate (Zhao et al., 2004).  We use the 
fluorescence of dopaminergic neurons within brain slices from GFP transgenic mice to aid 
electrode placement for the electrochemical monitoring of extracellular dopamine 
concentrations. This is especially useful in sparsely innervated areas where release sites 
can be difficult to find.  Additionally, visualizing the neurons of the mesolimbic pathway 
within horizontal brain slices allows a stimulating electrode to be placed along the axons of 
cells that release dopamine measured in the NAc.  The working electrode can also be 
placed in the VTA to look at antidromic release.   
However these are transgenic mice expressing a non-native protein, so it cannot be 
assumed that cell function is identical to wild-type mice.  Some transgene products interact 
with numerous processes that can cause pleiotropic effects on phenotype (Giddings, 2002).  
GFP mice generated by Sawamoto and co-workers were evaluated in neuronal postnatal 
cell culture and were found to reliably identify dopaminergic neurons expressing expected 
characteristics  (Jomphe et al., 2005).  The mice used in that study were heterozygous 
because the homozygotes had low survivability.  As mentioned by the authors, this could be 
due to random insertion of the transgene in the coding region or promoter of an important 
gene.  The mice used in this study were generated independently in the Iacovitti lab and 
have the advantage of being homozygous.   Therefore, a systematic comparison of GFP 
mice and C57 mice, their wild-type background strain, has been conducted to assess 
parameters important to brain slice experiments. 
Materials and methods 
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Chemicals 
Cocaine hydrochloride was obtained from Sigma-Aldrich (St Louis, MO, USA). For 
administration of cocaine to brain slices, 10 mM stock solutions were prepared by dissolving 
the appropriate weight of cocaine hydrochloride into a known volume of deionized water. 
Animals 
Animals were handled in accordance with protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina. A transgenic mouse line in 
which dopamine neurons express the gene for the enhanced green fluorescent protein was 
used (Kessler et al., 2003).  C57/BL6 (wild-type) mice were obtained from The Jackson 
Laboratory (Bar Harbor,ME, USA) at 5–6 weeks of age. Upon receipt, mice were housed at 
the University of North Carolina Animal Husbandry Facility in Kerr Hall. Mice were provided 
food and water ad libitum and were kept under conditions of controlled temperature, 
humidity, and a 12-h light/dark cycle. 
Brain slices 
Mice were deeply anesthetized by ether inhalation and decapitated.  The brain was 
immediately removed and placed in ice-cold aCSF.  The aCSF solution consisted of (in 
mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, D-
glucose 11. The pH was adjusted to 7.4 with 5 M NaOH and the buffer was continuously 
saturated with 95% O2/5% CO2. The cerebellum was sliced off with a razor blade and the 
brain was mounted on a Teflon block using Krazy Glue ®. Brain slices were made using an 
NVSL vibratome (World Precision Instruments, Sarasota, FL, USA). Coronal slices 
containing the striatum were made 300-µm thick, obtained at +0.5 to +1.0 mm from bregma.  
Coronal slices containing the substantia nigra and ventral tegmental area were obtained at -
2.8 to -3.3 mm from bregma.  Brain slices were stored in ice-cold aCSF. A single slice was 
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submerged under aCSF maintained at 34°C and continuously flowing (2 mL/min) through a 
superfusion chamber (Warner Instruments, Hamden, CT, USA).  Each brain slice was 
equilibrated for 30 min prior to obtaining measurements. To expose the brain slice to a given 
drug or calcium concentration, the appropriate volume of drug or calcium stock solution was 
added to the buffer reserve and introduced by a peristaltic pump to the slice through a 
threeway valve. A cumulative dosing regimen was used to collect concentration-response 
data. Brain slices were allowed to equilibrate for 30 min at a given drug or calcium 
concentration prior to exposing the slice to the next higher concentration. 
Electrochemistry 
Carbon-fiber, cylindrical microelectrodes were made as previously described (Kawagoe et 
al., 1993) using T650 carbon fibers (Amoco, Greenville, SC, USA) cut to a length of 25 µm.  
Electrodes were epoxied (Miller-Stevenson, Danbury, CT, USA) to ensure a good seal, and 
dipped immediately in acetone for a few seconds to remove residual epoxy from the carbon 
fiber.  A triangular waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -
0.4 V, was applied to the carbon-fiber working electrode, versus a Ag/AgCl reference 
electrode, at a scan rate of 600 V/s.  An update rate of 10 Hz was used for all experiments 
except for those used to obtain uptake kinetics, for which an update rate of 60 Hz was used.  
The carbon fiber was inserted until the tip was 60-70 µm below the surface of the 
brain slice in the dorsolateral caudate region of the striatum between the prongs of a bipolar 
stimulating electrode (FHC, Bowdoinham, ME, USA), situated 200 µm apart. To evoke 
dopamine release, a single biphasic stimulating current pulse (2 ms each phase, 350 µA in 
amplitude) was applied to the stimulating electrode. The current arising from dopamine 
oxidation (at about 0.6 V) in successive voltammograms was measured and plotted versus 
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time. Electrodes were calibrated against dopamine standards of known concentrations in a 
flow cell after each brain slice experiment.  
High Performance Liquid Chromatography  
Tissue samples were punched from slices (500 µm thickness) with a 2.5 mm diameter cork 
borer. The tissue was blotted dry with a Kimwipe,weighed dry, and homogenized with a 
sonic dismembrator (Fisher Sci., Model 60, Pittsburgh, PA, USA) in 200 µL of 0.1 N HClO4 
spiked with 1 µM hydroquinone. The homogenized tissue was centrifuged at 6000 rpm for 
10 min, and the supernatant was removed and filtered using a 0.2-µm syringe microfilter 
(Millex-LG). Injections (10 µL) were made onto a reverse phase column (C-18, 5 µm, 4.8 x 
250 mm, Waters symmetry 300). The mobile phase  (prepared in HPLC grade water) 
contained 0.1 M citric acid, 1 mM hexyl sodium sulfate, 0.1 mm EDTA, and 10% methanol 
(pH 3.5) at a flow rate of 1 mL/min. Catecholamines were detected with a thin-layer radial 
electrochemical flowcell (BASi, West Lafayette, IN, USA) at a potential of 700 mV versus a 
Ag/AgCl reference electrode.  Catecholamine standards were prepared from 10 mM stock 
solutions in 0.1 N perchloric acid. 
Dopamine Release and Calcium Dependence 
For each phenotype, dopamine release was recorded at four different locations in the 
caudate.  At each location, measurements were taken every five minutes for five trials.  The 
resulting data was averaged and counted as a single reading.  To determine the 
dependence of dopamine release on the extracellular concentration of calcium, dopamine 
release at a single site in the dorsolateral caudate was confirmed at a calcium concentration 
of 2.4 mM and then replaced with calcium-free buffer.  Once release was extinguished, 
increasing concentrations of calcium were introduced as described above.   
67 
 
Kinetic analysis 
Dopamine uptake follows Michaelis–Menten kinetics (Wightman et al., 1988; Kawagoe et 
al., 1992; Jones et al., 1995). Thus, the presumed scheme is (Matthews and Holde, 1996): 
 
(DA)o + T ↔ (DA)T → (DA)I + T 
 
where (DA)o is extracellular dopamine, (DA)i is intracellular dopamine, and T is the 
dopamine transporter. The Michaelis–Menten rate equation for dopamine uptake may be 
written as: 
 
d[DA]/dt = [DA]p – Vmax/(KM/[DA] + 1) 
 
where [DA] is the brain extracellular concentration of dopamine, [DA]p is the change in 
concentration of dopamine at the electrode produced by each stimulus pulse, and Vmax and 
KM are Michaelis–Menten rate constants which describe dopamine uptake DAT. In the 
absence of added drugs, KM was fixed at 0.2 µM and the values for [DA]p and Vmax were 
adjusted to obtain a best fit. The rate equation was numerically integrated and compared 
with the experimental data using locally written software (Wu et al., 2001).  Since the KM of 
DAT in eGFP mice may not be 0.2 µM, the resulting Vmax may be in error.  To determine a 
more accurate KM, a competitive inhibitor analysis was used. 
In the presence of a competitive inhibitor (I), the additional equilibrium must be 
considered: 
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I + T ↔ IT 
Under this paradigm (KM)app is defined as KM(1 + [I]/Ki), where Ki is the dissociation constant 
for the above reaction, and is defined as Ki = [I][T]/[IT]. Thus, a plot of (KM)app versus [I] 
should be linear with a slope of KM/Ki and a y-intercept of KM (Matthews and Holde, 1996).  
A linear regression was used to determine a value of KM from each set of cumulative doses 
of cocaine for a given slice. This new KM value was then used to determine Vmax in the 
absence of drug.  The changes in the apparent KM were determined again using this more 
accurate Vmax value.  By holding the y-intercept of the linear regression at the value of KM, a 
Ki value was calculated.  The Vmax, KM, and Ki, values for each mouse genotype were pooled 
to obtain average values and standard error. 
Statistics 
Phenotypical differences were evaluated statistically using paired t-tests in GraphPad Prism 
software (GraphPad Software Inc., San Diego, CA, USA).  Data were considered significant 
at the 95% confidence level and are reported as the mean ± SEM for n animals. 
 
Results 
Tissue  Content 
Tissue punches of the caudate were used to determine dopamine tissue content at 
dopaminergic terminals, and tissue punches of the midbrain were used to determine 
dopamine tissue content at dopaminergic cell bodies.  Midbrain punches were taken to 
encompass the ventral tegmental area (VTA) but may also include some parts of the 
adjacent dopaminergic structure, the SNc.  There are no significant differences between  
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Figure 4.1. Dopamine tissue content.  HPLC analysis of tissue punches from brain slices 
containing the regions referenced in the column titles.  Recovery of dopamine is determined 
from an internal standard, hydroquinone.  Dopamine tissue content is normalized to the 
mass of the tissue sample.  The dopamine tissue content of WT and GFP mice are not 
significantly different when compared by region (p > 0.05, n = 4). 
 
 
70 
 
GFP and WT mice in either region (p > 0.05, between mice in each region, Figure 4.1).  
There is much greater dopamine content in the caudate than in the midbrain for both 
phenotypes.  The WT caudate contains 9.6 ± 1.7 µg DA/g tissue and the GFP caudate 
contains 7.3 ± 0.8 µg DA/g tissue.  These values are slightly less than those reported for 
striatal dopamine content in C57 black mice (Gao et al., 1998).  They used dry weights, and 
wet weights were used in this work, which will cause actual dopamine content to be 
underrepresented. 
Dopamine Release and Calcium Dependence 
Dopamine release due to single pulse stimulation in the caudate of GFP mice, as measured 
by FSCV, is not significantly different than wild-type mice (p > 0.05, Figure 4.2).   
Representative traces of stimulated release for a one-pulse stimulation form a WT mouse 
and a GFP mouse are shown in Figure 4.2.  The rising portion of the signal is the increase in 
extracellular following stimulation.  A cyclic voltammogram at the time the release event is at 
its maximum identifies the released substance as dopamine.  The falling portion of the 
signal is due to uptake by DAT.  The linear portion near the maximum is a Vmax dominated 
region.  As the extracellular concentrations falls, uptake rates become exponential in a KM 
dominated region.    Moreover, the calcium dependence of dopamine release in the two 
animal types overlay (Figure 4.3).  Dopamine release is normalized to the release measured 
at 3.0 mM calcium to remove the variability of release between slices.    
 
Uptake Kinetics 
The validity of using the competitive inhibitor analysis was established by analyzing wild-
type mice and comparing to reported values.  The Vmax (5.0 +0.3 µM/s), KM (0.25 +0.03 µM),  
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Figure 4.2. Stimulated dopamine release.  A) Representative traces from a WT and GFP 
mouse following a single-pulse stimulation, as indicated by the orange square. The CV 
identifies dopamine at the peak of the signal.  Vmax dominates uptake during the linear 
portion at the top of the curve and KM dominates uptake at low concentrations where the 
trace curves toward baseline.   B)The peak concentration of dopamine released following a 
one-pulse stimulation as measured by FSCV.  Five traces were averaged at each of four 
locations within one slice per animal were averaged to represent one data point.  The 
concentration of dopamine released upon stimulation in WT and GFP mice are not 
significantly different (p > 0.05, n = 6). 
B 
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Figure 4.3. Calcium dependence of dopamine release.  The amount of dopamine release in 
each brain slice was normalized to the release measured at 3 mM calcium to take out the 
variability of release from one slice to another.  There is no significant difference between 
the values at each concentration (p > 0.05, n = 5). 
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Table 1. Uptake parameters of WT and GFP mice.  The parameters describing uptake in 
these brain slices are the result of a competitive inhibitor analysis using a simplex modeling 
program.  A post-experiment calibration provided the sensitivity and time constant of each 
electrode used.  The values shown are mean + s.e.m. of the values obtained in each slice. 
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Figure 4.4. Uptake inhibition of DAT by cocaine.  The y-intercept is held at the value 
determined for KM.  The KM value at each cocaine concentration was determined by holding 
constant the VMAX value determined form the pre-drug file, which is an average of five traces.  
Each point is the average and the error bars represent s.e.m. for n = 5. 
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and Ki for cocaine (0.26 +0.05 µM) values reported in Table 1 for the WT mouse are similar 
to, although slightly higher than, values reported elsewhere.  Uptake in GFP mice were 
compared to WT mice using this analysis.  While the KM (0.25 +0.02 µM) for the GFP mouse 
is not significantly different than the WT (p > 0.05, n = 5), the Vmax (2.8 +0.4 µM/s) is lower (p 
< 0.002, n = 5).  Figure 4.4 shows the change in (KM)app with cocaine concentration and the 
linear regression used to find Ki.  The Ki for the GFP mouse and WT mouse is not 
significantly different (p < 0.002, n = 5).   
Discussion 
Generally, these GFP mice are in all measured ways similar to WT C57/BL6 mice except 
that a lower VMAX was found in the GFP mice.  Since the GFP transgene is coupled to the 
promoter for TH one would expect that if there were some difference in the mice it would be 
related to synthesis or tissue content of dopamine.  However, the random nature of 
transgene insertion into chromosomes can bring about unforeseen differences whether 
pleiotropic or compensatory.  Although behavior was not directly tested, anecdotally the 
mice do not appear to exhibit a phenotypic difference. 
 The similarity in tissue dopamine content and stimulated release indicates that the 
terminal density of the dorsal striatum is similar between the mice.  Taken together with the 
difference in VMAX there may be fewer transporters per terminal in GFP mice.  Although the 
rate of synthesis was not tested directly, the global assessment of content and release 
shows that the overall volume of synthesis does not appear impaired.   
 The similar sensitivities to extracellular concentrations of calcium indicate that the 
calcium channels, calcium buffering and vesicular-fusion mechanisms are unaffected.  
Tissue content of dopamine and calcium response being similar between WT and GFP 
further buttresses the assertion that release is the same.     
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 The use of a competitive inhibitor analysis is an approach to determine uptake 
parameters in a sample of unknown kinetics.  To validate this approach the analysis was 
first carried out on WT mice.  Values of KM in the absence of uptake inhibitors have been 
determined in synaptosomal preparations to be approximately 0.2 µM (Horn, 1990).  This 
was taken as a starting value from which to derive a Vmax that could be used to assess shifts 
in KM in the presence of cocaine.   During the first iteration, for which KM was held at 0.2 µM, 
the Vmax value (4.8 + 0.2 µM/s) closely matches the previously reported value of 4.3 
+0.5µM/s (Jones et al., 1999).   Allowing the y-intercept to float during the linear regression 
yielded a slightly higher KM which in turn yielded a slightly, but not significantly, higher Vmax. 
Using this Vmax in a second assessment of shifts in KM produced KI values similar to values 
reported from synaptosomal preparations in the rat (Richelson and Pfenning, 1984).  These 
results are sufficiently accurate as to validate a comparison between mouse types.  All 
values were found to be similar except a lower VMAX was found in the GFP mice.   Vmax is 
proportional to dopamine transporter concentration, so a lower Vmax implies a lower DAT 
expression level.  It is not clear at this time why DAT expression should be different.  
Additionally, other uptake inhibitors could be used to verify this difference in VMAX.  In 
addition, different regions of the brain could be tested for differences in VMAX to determine if 
this difference only exists in the dorsal striatum.  Although the expression level of DAT may 
have been altered in GFP mice, the transporters take up dopamine with similar kinetics as in 
WT mice and are similarly inhibited by cocaine.   
   Given the similarities in release in the striatum, it would be interesting to probe 
release in other regions more difficult to study, such as the hypothalamus and limbic cortex.  
With the visualization of neurons being possible, release in horizontal or sagittal slices can 
be exploited.  There are other properties of these mice that could be investigated as well, 
such as assessing D2-autoreceptors and VMAT activity.  One can pursue experiments with 
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these mice expecting release parameters to be similar to WT’s and expecting cocaine inhibit 
uptake with a similar efficiency with the caveat that the actual rates of uptake may be 
different. 
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Chapter 5 
Development of a Remote Stimulation Protocol 
Introduction 
The importance of the mesolimbic dopamine system to behavior has been widely 
studied.  Mesolimbic dopamine neurons encode stimulus-reward associations (Schultz et al., 
1997), subserve the alerting aspects of reward circuitry (Wightman and Robinson, 2002), 
and relay a reward prediction error signal (Mirenowicz and Schultz, 1996).  Increases in 
dopamine transmission underlie the reinforcing properties of many drugs of abuse (Di 
Chiara and Imperato, 1988; Wise, 2004).  The mesolimbic pathway includes dopaminergic 
cells of the ventral tegmental area (VTA) that project axons through the medial forebrain 
bundle (MFB) to the nucleus accumbens (Acb).  This pathway can now be visualized in 
transgenic mice that express green fluorescent protein (GFP) in dopaminergic neurons 
(Figure 1).  However, since dopamine neurons are part of a complex circuit of cells, it is 
difficult through in vivo experiments to determine the specific properties of the dopamine 
neuron that contribute to the function of the system. 
Brain slice experiments are conducted to understand the activity of dopamine 
neurons independently of the brain system with which they are a part.  By taking a brain 
slice the region of interest is isolated from many of the inputs from other regions of the brain.  
Additionally, pharmacological agents can be added to the buffer supporting the brain slice.  
This is a more spatially constrained application than the global effects that may arise from 
systemic injection of drugs in the whole animal.  Finally, brain slice experiments allow the  
81 
 
 
 
 
 
 
 
Figure 5.1. A sagittal brain slice of a TH-GFP mouse stained with an antibody to GFP 
(gensat.org).  Components of the mesolimbic pathway are labeled and include the cell body 
region (VTA), axonal region (MFB), and terminal region (Acb).   Also labeled are 
components of the nigrostriatal pathway which includes the cell body region (SN), axonal 
region (MFB), and terminal region (CP).   
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precise placement of electrodes with the aid of microscopy.  This facilitates the use of 
fluorescent techniques to aid in identification of specific cell types. 
Traditional brain slice protocols for study of the mesolimbic system utilize local 
stimulation of dopamine terminals within coronal slices of the Acb.  Since coronal slices 
sever the nerve terminals from the rest of the cell, the stimulation to elicit dopamine release 
must be delivered near the recording location.  This local stimulation also causes other cell 
types near the dopamine terminals to release their contents, such as γ-aminobutyric acid 
(GABA), glutamate, and acetylcholine.  These substances can effect the function of the 
dopamine terminal.   
An alternate approach is to take horizontal slices that encompass neurons of the 
mesolimbic pathway.  Axons or cell bodies can be stimulated in order to elicit dopamine 
release at the terminals some distance away without stimulating other adjacent cell types to 
release their contents.  This approach is possible because of the availability of GFP 
transgenic mice.  This allows the mesolimbic dopamine neurons to be identified by their 
fluorescence, which will direct electrode placement.  First, the stimulating electrode must be 
placed a sufficient distance from the working electrode to avoid stimulating other cell types.  
Second, the working electrode must be placed to avoid measuring norepinephrine release, 
which is electrochemically indistinguishable.  In this work horizontal brain slices of GFP 
transgenic mice containing mesolimbic dopamine neurons are used to perform remote 
stimulation, establish criterion for electrode placement, and investigate dopamine release 
dynamics with this novel approach.   
 
Materials and Methods 
Chemicals 
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Desipramine hydrochloride and GBR-12909 dihydrochloride were obtained from Sigma-
Aldrich (St Louis, MO, USA). For administration on brain slices, 10 mM stock solutions were 
prepared by dissolving the appropriate weight of drug into a known volume of deionized 
water. 
Animals 
Animals were handled in accordance with protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina. A transgenic mouse line in 
which catecholamine containing cells express the gene for the enhanced green fluorescent 
protein was used (Kessler et al., 2003).  The mice are homozygous for GFP, making 
genotyping unnecessary.  During the initial breeding to build the colony, genotyping was 
used to confirm that all mice carry the gene (data not shown).  Upon receipt, mice were 
housed at the University of North Carolina Animal Husbandry Facility in Kerr Hall. Mice were 
provided food and water ad libitum and were kept under conditions of controlled 
temperature, humidity, and a 12-h light/dark cycle. 
Brain slices 
Mice were deeply anesthetized by ether inhalation and decapitated.  The brain was 
immediately removed and placed in ice-cold aCSF.  The aCSF solution consisted of (in 
mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, D-
glucose 11. The pH was adjusted to 7.4 with 5 M NaOH and the buffer was continuously 
saturated with 95% O2/5% CO2. The cerebellum was sliced off with a razor blade and the 
brain was mounted on a Teflon block using Krazy Glue ®. Brain slices were made using an 
NVSL vibratome (World Precision Instruments, Sarasota, FL, USA). Coronal slices 
containing the striatum were made 300-µm thick, obtained at +0.5 to +1.0 mm from bregma.  
For immunohistochemistry, the brain slices were made 200-µm thick.  Brain slices were 
stored in ice-cold aCSF. A single slice was submerged under aCSF maintained at 34°C and 
84 
 
continuously flowing (2 mL/min) through a superfusion chamber (Warner Instruments, 
Hamden, CT, USA).  Each brain slice was equilibrated for 30 min prior to obtaining 
measurements.  When pharmacological agents were used, they were added to the buffer to 
a known concentration and superfused for 30 min prior to measuring their effect.  
Epifluorescent Microscopy 
To visualize the fluorescence in brain slices, an upright microscope (Nikon Eclipse E600FN, 
Melville, NY) was used with a xenon lamp source to excite fluorescence.  A Nikon endow 
GFP bandpass filter set (filter 470 CWL for excitation, 525 CWL for emission, and a 495 LP 
dichroic mirror) was employed when viewing samples from GFP mice.  A CCD camera 
(Photometrics Sensys, Tucson, Arizona) was used to capture images.   
Electrochemistry 
Carbon-fiber cylinder microelectrodes were made as previously described (Kawagoe et al., 
1993) using T650 carbon fibers (Amoco, Greenville, SC, USA) cut to a length of 25 µm.  
Electrodes were epoxied (Miller-Stevenson, Danbury, CT, USA) to ensure a good seal, and 
dipped immediately in acetone for a few seconds to remove residual epoxy from the carbon 
fiber.  A triangular waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -
0.4 V, was applied to the carbon-fiber working electrode, versus a Ag/AgCl reference 
electrode, at a scan rate of 600 V/s.  An update rate of 10 Hz was used for all experiments.   
The carbon fiber was inserted until the tip was 60-70 µm below the surface of the 
brain slice between the prongs of a bipolar stimulating electrode (FHC, Bowdoinham, ME, 
USA), situated 200 µm apart. To evoke dopamine release, a single biphasic stimulating 
current pulse (2 ms each phase, 350 µA in amplitude) was applied to the stimulating 
electrode. The current arising from dopamine oxidation (at about 0.6 V) in successive 
voltammograms was measured and plotted versus time.  
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Kinetic analysis 
Dopamine uptake follows Michaelis–Menten kinetics (Wightman et al., 1988; Kawagoe et 
al., 1992; Jones et al., 1995). Thus, the presumed scheme is (Matthews and Holde, 1996): 
(DA)o + T ↔ (DA)T → (DA)I + T 
where (DA)o is extracellular dopamine, (DA)i is intracellular dopamine, and T is the 
dopamine transporter. The Michaelis–Menten rate equation for dopamine uptake may be 
written as: 
d[DA]/dt = [DA]p – Vmax/(KM/[DA] + 1) 
where [DA] is the brain extracellular concentration of dopamine, [DA]p is the change in 
concentration of dopamine at the electrode produced by each stimulus pulse, and Vmax and 
KM are Michaelis–Menten rate constants which describe dopamine uptake DAT. These 
same processes can be used to describe uptake by the norepinephrine transporter (NET).  
In the absence of uptake inhibitors, KM was fixed at 0.2 µM and the values for [DA]p and Vmax 
were adjusted to obtain a best fit. In the presence of uptake inhibitors, the change in uptake 
kinetics should appear as a change in KM  (Jones et al., 1995).  Therefore, Vmax was held 
constant at pre-drug values and KM was adjusted to obtain a best fit.  The rate equation was 
numerically integrated and compared with the experimental data using locally written 
software (Wu et al., 2001).   
Immunohistochemical Labeling 
Slices were fixed in 2% formaldehyde in Sorenson's buffer (0.15 m Na2HPO4/KH2PO4 at pH 
7.4) for 4 h. The slices were rinsed three times with 1X PBS (Tissue Culture Facility, Chapel 
Hill, NC, USA). Then, normal goat serum (NGS, Life Technologies, Rockville, MD, USA) was 
combined with 0.2% BSA/PBS solution (1 : 10, NGS : BSA/ PBS) containing 0.3% Triton-
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100X.  The slices were incubated in this blocking solution for 2 h.  The Primary antibody 
solutions were incubated for overnight (15hours) at 4°C with slow agitation and rinsed with 
PBS.  For double labeling, secondary antibody was diluted 1:1000 and incubated overnight 
with the slices.  For DβH/GFP double labeling experiments, the primary antibody for GFP 
(Rabbit, Invitrogen) is conjugated to Alexa Fluor ® 488, and the primary antibody for DβH is 
unconjugated (Sheep, Invitrogen).   Primary antibodies were diluted into 0.5 mL of PBS and 
then 5 mL of blocking solution to final dilutions as follows: anti-GFP, 1:400; anti-DβH, 1:500.  
The secondary antibodies used were Alexa Fluor ® 555 conjugated goat anti-rabbit. Then, 
the slices were rinsed with PBS, placed on slides, and examined by confocal microscopy. 
Confocal microscopy 
Throughout this work, anatomical locations were determined by comparison with a mouse 
brain atlas (Paxinos and Franklin, 2004). The brain slices containing the desired regions 
were placed onto microscope slides with glass wells to maintain their structural integrity. Into 
these wells, Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA) was added. After the 
slices were placed in mounting medium, they were coverslipped, and sealed with clear nail 
varnish.  The confocal images were collected on a Leica SP2 Laser Scanning Confocal 
Microscope (Leica Microsystems, Confocal Microscopy, Germany) in the Michael Hooker 
Microscopy Facility at the University of North Carolina at Chapel Hill.  Photomultiplier tubes 
were used to detect the fluorescence from the fluorochromes in the multiple-labeling 
experiments. 
 
Results 
Epifluorescence and Stimulation of Mesolimbic Dopamine Pathway 
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One can imagine passing a horizontal plane through the mesolimbic pathway in Figure 5.1 
oriented to be coming out of the page.  If a slice was taken through the rodent brain at this 
orientation at a sufficient depth and thickness to encompass a segment of those dopamine 
neurons, one would have the slice shown in Figure 5.2, an epifluorescent image of a 
horizontal GFP mouse brain slice containing the mesolimbic pathway.  A black line near the 
number 1 is a shadow of the carbon-fiber microelectrode among the nerve terminals where 
release is measured.  The cell bodies are sufficiently bright to make visualizing the axons 
difficult and are thus placed out of view on the right.  The axons are the thin, filamentous 
structures that project from the cell bodies to the terminals on the left.  The numbers indicate 
the placement of the stimulating electrode.  The corresponding cyclic voltammograms below 
the image were measured at the peak of release upon stimulation.  A single-pulse 
stimulation was used at position 1.  A 24-pulse, 60 Hz stimulation was used at positions 2 
and 3 because a single-pulse stimulation did not elicit a detectable signal. Even with this 
more intense stimulation, less release is observed as the stimulating electrode is moved 
posterior towards the cell bodies.  This can be explained if some axons are severed in the 
slicing process.  The more posterior, the less axons are available that make connections to 
the terminals, thus less release upon stimulation of the axons.  The CV’s indicate that the 
released substance is a catecholamine, due to the oxidation potential at 0.6 V and the 
reduction potential at -0.2 V.   
Defining Remote Stimulation 
The release observed in the previous experiment could be due to the stimulation of axons, 
or the stimulating current may have been sufficient to directly elicit a response from the 
terminals about the working electrode.  In slices containing no axons, only stimulating 
terminals can elicit release, so the separation distance between stimulating electrode and  
88 
 
 
 
 
 
 
 
Figure 5.2. Remote stimulation of mesolimbic dopamine neurons.  At the top is an 
epifluorescent image from a horizontal brain slice of a GFP mouse containing the 
mesolimbic pathway.  The numbers indicate the placement of the stimulating electrode and 
the corresponding cyclic voltammagram measured by the working electrode upon 
stimulation. A single-pulse stimulation was used at position 1.  A 24-pulse 60 Hz stimulation 
was used at positions 2 and 3 because a single-pulse stimulation did not elicit a detectable 
signal. 
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working electrode at which release ceases to be observed would define the outer limits of 
local stimulation.  Coronal slices of the nucleus accumbens (Acb) were used.  These slices 
contain dopamine terminals severed from the rest of the cell.  The stimulating electrode is 
then stepped toward the working electrode at distances determined from CCD images of the 
slice.  The magnitude of stimulated release at each distance is compared in Figure 5.3.  
Regardless of which stimulation intensity was used, release was not detected when the 
stimulating electrode was separated from the working electrode by more than 600 µm.  All 
experiments referred to as using remote stimulation utilized an electrode separation greater 
than 600 µm, usually 800-1000µm.   
DβH Distribution Relative to GFP 
The relative level of GFP expression throughout many brain regions has been reported 
previously (Kessler et al., 2003).  However, the distribution of interferants is also relevant.  
Norepinephrine is electrochemically indistinguishable from dopamine, and the 
microelectrode sensitivity differs between them.  Proper electrode placement is important to 
avoiding a mixed signal.  Here, the distribution of dopamine neurons and noradrenergic 
terminals in coronal and horizontal slices are investigated.  Dopamine-β-hydroxylase (DβH) 
is the enzyme that converts dopamine into norepinephrine.  Therefore DβH was used as a 
marker for noradrenergic neurons.  It was previously shown that noradrenergic neurons 
express very little if any GFP, so GFP is a marker for dopaminergic neurons (Kessler et al., 
2003). The anatomical distribution of GFP and DβH were determined immuno-
histochemically.   
Coronal slices from +1.5 mm to 0.0 mm from bregma were tested.  Brain atlas 
images are shown to the right of the confocal images (Paxinos and Watson, 2007).  In the 
nucleus accumbens (Acb) a DβH signal emerges at approximately 0.70 mm from Bregma  
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Figure 5.3.  Release and Electrode Separation.  The peak concentration of dopamine 
release upon stimulation is measured as a function of the separation between the 
microelectrode and the stimulating electrode.  The measurements are taken in a coronal 
slice of the Acb.  The stimulating electrode was moved as the microelectrode remained 
stationary.  Greater stimulation pulses elicit measurable release from a greater distance, but 
release drops to zero at an electrode separation of 600 µm. 
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about the anterior commissure (ac) (Figure 5.4), which is consistent with the known 
distribution in wild-type mice.  The confocal images reveal little overlap in labeling, 
supporting the conclusion that GFP is not expressed in noradrenergic neurons.  Since the 
signal anterior to 0.70 mm Bregma consists of only GFP labeling the electrochemical signal 
at these locations should be due to dopamine and not norepinephrine.  
Horizontal slices from -6.8 mm to -8.0 mm from dura, a membrane surrounding the 
brain, were evaluated for the presence of GFP and DβH.  The image in Figure 5.5A depicts 
a horizontal slice containing the mesolimbic pathway (Paxinos and Watson, 2007).  The 
squares indicate the location from which the confocal images were taken.  In panel 5.5B, 
images on the left are taken at a location indicated by box 1 and the images on the right are 
taken at a location indicated by box 2, which is posterior to box 1.  GFP labeling indicates 
dense GFP expression in the dorsal portions of the slice in the Acb at all depths tested.  
These images also confirm the presence of axons in these slices, which facilitate remote 
stimulation.  As with the coronal labeling, the DβH signal emerges posterior to a GFP only 
signal.  There is also DβH labeling along the midline of the slice.  Therefore, a voltammetric 
measurement should avoid norepinephrine detection by placing the microelectrode within 
the anterior Acb and away from the midline.  There appears to be greater DβH labeling in 
the most ventral slices.  Therefore, slices used in the subsequent experiments were taken 
from approximately -6.8 mm to -7.2 mm from dura.   
Pharmacology 
Placing the microelectrode within the anterior Acb and away from the midline, 
remotely stimulated catecholamine release is measured.  To determine if the release is from 
dopaminergic neurons, noradrenergic neurons, or both, selective uptake inhibitors 
desipramine (desi) and GBR-12909 (GBR) were used.  If the released substance is 
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Figure 5.4.  Immunohistochemical co-localization of GFP (cyan) and DβH (yellow) in coronal 
slices of the GFP mouse striatum.  The ventral striatum (Acb) is shown at two locations.  
The NAc labels solely for GFP until about 0.7 mm from bregma.  Then the signals are both 
present from 0.7 mm to 0.0 mm from bregma, the most anterior slice tested.  To the right of 
each image is a representation of the region from the mouse brain atlas (mbl.org).  
+1.4 mm from bregma 
+0.7 mm from bregma 
ac 
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Figure 5.5.  Immunohistochemical co-localization of GFP (cyan) and DβH (yellow) in 
horizontal slices of the GFP mouse striatum.  A.) Representative slice taken from the rat 
brain (Paxinos and Watson, 2007). The two squares indicate the location the confocal 
images were collected.  B.) The images to the left are horizontal slices from square 1 and 
the images on the right are from square 2.  The images in a row are from the same slice of a 
depth indicated in mm from dura by the white numbers.  
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norepinephrine, then uptake is controlled by the norepinephrine transporter (NET).  If the 
released substance is dopamine, then uptake is controlled by the dopamine transporter 
(DAT).  Desipramine is a selective uptake inhibitor of NET, and GBR-12909 is a selective 
uptake inhibitor of DAT.   The order these drugs were introduced to the slice was 
randomized.  A 300 nM solution of one of the drugs was added, and after 30 min incubation, 
two files were collected.  Then a 300 nM solution of both drugs was added, and after 30 min 
incubation, two more files were collected.  The change in KM with the addition of each 
solution was used to determine the presence of either transporter. 
 Representative traces are shown in Figure 5.6A where desipramine is added first, 
then GBR-1209 is added in the presence of desipramine.  The rate of uptake is unaffected 
by desipramine but slowed by GBR-12909.  In all slices examined (n = 5), desipramine did 
not increase KM (93 +10% of pre-desipramine files), and GBR-12909 caused a large change 
in KM (405 +108% of pre-GBR files).  The change in KM caused by GBR-12909 is significant 
relative to change in KM caused by desipramine (p > 0.05).  The much greater effect of 
GBR-12909 indicates that uptake is regulated by DAT in this location in the Acb. 
Heterogeneity 
Figure 5.7a shows release profiles recorded at different depths above and below the surface 
of a horizontal slice elicited by single-pulse local stimulation while the stimulating electrode 
was stationary at the surface of the slice.  The surface of the slice was determined visually 
by lowering the electrode until it appeared to make contact with the slice.  This process has 
about a 10 µm error.  The distance the electrode was moved in the z-axis was determined 
with piezoelectric manipulators with an error of 0.1 µm.  Dopamine could be detected from 
50 µm above the slice to 200 µm below the surface of the slice where the experiment was  
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Figure 5.6. Uptake inhibited by GBR-12909(GBR) but not by desipramine (Desi).  A.) 
Representative traces of remotely stimulated release.  The bar indicates the duration of 
stimulation (24-pulse, 60 Hz).  Uptake in the control trace (aCSF) and with Desi on board are 
similar, but uptake is slowed noticeably with the addition of GBR.  B.)  Uptake was modeled with 
Michaelis-Menton kinetics.  Desi did not cause a significant change (93 +10% of pre-
desipramine) in uptake, but GBR-12909 caused a large shift (405 +108 % of pre-GBR). The 
difference in KM shift due to drug is significantly different between desi and gbr (p < 0.05, n = 5). 
A 
B 
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terminated.  The concentration of dopamine release increases with the lowering of the 
electrode until a depth of 50 µm.  The latency between the stimulation and the peak of 
release is an indication of the average distance from the release sites to the surface of the 
electrode (Venton et al., 2003).  This latency is much longer above the slice where 
dopamine is diffusing from release sites in the slice.  The latency decreases as the electrode 
is lowered into the slice.  The latency increases again starting at a depth around 150 µm, 
indicating the release sites are increasingly further from the electrode.   
 Unlike local stimulation, remote stimulation elicits little to no dopamine release at or 
above the surface of the slice.  The example traces shown in Figure 5.7b reveal a small 
range of depths where dopamine release is detected in this slice and the concentration is 
dramatically higher at a 150 µm depth than any other.  While local stimulation presumably 
excites most of the terminals near the stimulating electrode, remote stimulation should only 
excite the terminals connected to axons near the stimulating electrode, thus confining the 
volume in which release can be measured.   
 Four slices from four different animals were used to probe the heterogeneity of 
dopamine release at different sampling depths (Figure 5.8).  The separate samples are 
shown to avoid masking the heterogeneity by averaging.  Release increases then decreases 
with sampling depth for samples 1 and 4.  In samples 2 and 3, release increases with depth.  
A depth may have not been reached where the release would decrease again as with the 
other samples.   
Lateral heterogeneity was also investigated with remote stimulation.  The working 
electrode is moved along the medial-lateral axis relative to a starting location where 
remotely stimulated release is observed.  Again, release was sampled at a depth of 60-70  
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Figure 5.7.  Depth profile with local and remote stimulation.  Recordings of dopamine 
release at different depths above (negative values) and within (positive values) a coronal 
slice of the Acb. A.)  Release elicited by single-pulse local stimulation, delivered at the 
arrow. B.) Release elicited by a 24-pulse, 60 Hz stimulation occurring over the time indicated 
by the line under the trace.  Release occurs over a narrow depth window well below the 
depths where the maximal release is measured with local stimulation. 
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Figure 5.8.  Release depth profile with remote stimulation.  The extracellular concentration 
of dopamine release elicited by a 24-pulse, 60 Hz remote stimulation at different depths 
within four different brain slices from four animals.  The depth is relative to the surface of the 
slice (0 µm).  The negative depth is above the slice.  The electrode is traversing ventral to 
dorsal as it is lowered through the tissue.  Release is heterogeneous within the Acb.  This 
provides additional evidence that the release is indeed due to remote stimulation since the 
greatest release is measured at greater than 100 µm below the surface of the slice. 
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Figure 5.9.  Lateral heterogeneity of release with remote stimulation.  The extracellular 
concentration of dopamine release elicited by a 24-pulse, 60 Hz remote stimulation at 
different recording locations along a medial-lateral axis at a depth of 60-70 µm within three 
different brain slices from three animals.  Lateral displacement is relative to consistent 
starting location about the center of the Acb (0 µm). Displacement is measured lateral 
(negative) to medial (positive) from CCD images of the slice.  Release is heterogeneous 
within the Acb, and the distribution is skewed medial, similar to the direction of the pathway. 
 
 
 
100 
 
stimulating electrode.  However, with remote stimulation the differences in release are due 
to differences in the terminal density of neurons whose axons are being stimulated.  Figure 
5.9 displays the measured release in three samples as the electrode surveys release sites 
µm below the surface of the brain slice.  With local stimulation, release varies with distance 
from the medial (towards the midline) and lateral (away from midline) from a starting site.  
Efforts were made to start the survey in a similar location between brain slices.  In all 
samples there appears to be an optimal location where the greatest release can be 
measured.   
Stimulation Parameters 
Figure 5.10A includes representative traces of release due to remote stimulation 
using a 10 Hz, 20-pulse stimulation and a 30 Hz, 20-pulse stimulation.  Figure 5.10B 
includes representative traces of release due to local stimulation using the same 
parameters.  There is a much greater difference in release magnitude between the two 
stimulation frequencies in the case of remote stimulation.  In fact, there is little change in 
release with stimulation frequency across animals when using local stimulation (Figure 
5.10C, slope = 0.009 +0.002) indicating that release is maximal even with a 10 Hz 
stimulation.  The change in release with stimulation frequency is significantly different 
between local and remote stimulation (p > 0.002, n = 4).  The relationship between 
stimulation frequency and dopamine release is linear in vivo (Wightman et al., 1988) and 
with remote stimulation (Figure 5.10C, r2 = 0.967). 
 The change in release with pulse number is significantly less with local 
stimulation than remote stimulation (p > 0.01, n = 5).  Figure 5.11A and 5.11B displays 
representative traces of release due to remote stimulation and local stimulation, 
respectively, using 60 Hz stimulations of the pulse numbers indicated. The change in  
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Figure 5.10.  The effect of stimulation frequency on dopamine release.  A.) Remotely 
stimulated dopamine release at 10 Hz and 30 Hz.  The stimulation duration is indicated by 
the empty squares and the bar below the traces.  B.)  Local stimulation of dopamine release 
at the same frequencies, indicated by the empty squares.  Stimulation frequency has little 
effect with local stimulation.  C.)  The peak concentration of dopamine release relative to 
that released with a 10 Hz stimulation.  All stimulations are 20-pulse.  The slope of the linear 
regressions are as follows:  Local stimulation (0.009 +0.002), Remote stimulation (0.071 
+0.009).  The statistical difference is significant, as determined by an ANCOVA (p > 0.002). 
 
 
 
A B
C 
10 Hz 10 Hz
30 Hz 30 Hz 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11.  The effect of stimulation pulse number on dopamine release.  A.) Remotely 
stimulated dopamine release with 10-pulses and 30-pulses.  The stimulation duration is 
indicated by the empty squares and the bar below the traces.  B.)  Local stimulation of 
dopamine release at the same pulse numbers, indicated by the empty squares.  Stimulation 
pulse number as less effect with local stimulation.  C.)  The peak concentration of dopamine 
release relative to that released with a 10-pulse stimulation.  All stimulations are at 60 Hz.  
The slope of the linear regressions are as follows:  Local stimulation (0.046 +0.006), Remote 
stimulation (0.073 +0.002).  The statistical difference is significant, as determined by an 
ANCOVA  (p > 0.01). 
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dopamine release with stimulation pulse number is greater with remote stimulation (Figure 
5.11C, slope = 0.073 +0.002) than with local stimulation (Figure 5.11C, slope = 0.046 
+0.006). 
Dopamine Release Dynamics 
A stimulation protocol of a 24-pulse, 60 Hz stimulation delivered every two seconds for five 
stimulation events was used to probe short-term dopamine release dynamics.  When this 
stimulation protocol is used in vivo, facilitation of release is observed (Montague et al., 
2004).  Facilitation of release is an increase in dopamine release with subsequent 
stimulations thought to be due to desensitization of D2-autoreceptors (Kita et al., 2007).  
Under normal buffer conditions, including 2.4 mM calcium, a constant decrease in release is 
observed with each stimulation in the brain slice (Figure 5.12A).  Providing tonic D2-
autoreceptor activation with 25 nM quinpirole attenuates how rapidly dopamine release 
decreases.  When the concentration of calcium in the buffer is reduced to 1.2 mM, the 
concentration of dopamine release decreases and the size of the peaks are more similar (as 
measured from valley to peak about the stimulation, Figure 5.12B).  When 25 nM quinpirole 
is added to this low calcium buffer, the peak concentration of dopamine release increases 
with each stimulation event until the fourth and fifth stimulation.  Therefore, a reduction in 
the buffer calcium concentration and the addition of quinpirole are necessary to achieve 
facilitation with remote stimulation in this horizontal brain slice.   Although obtained only 
once, this illustrates that changes in traditional brain slice methods are necessary for 
dopamine release dynamics to be studied in a physiologically relevant manner.  
 
Discussion 
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Figure 5.12.  Short-term dopamine release dynamics with remote stimulation in different 
calcium conditions.   24-pulse, 60 Hz stimulations delivered every 2 s as indicated by the 
bars under the traces.  A.) Recording of dopamine release due to stimulation protocol under 
standard buffer conditions (2.4 mM calcium) and with the addition of 25 nM quinpirole.  B.)  
Recording from the same slice with the same stimulations, now under a low calcium 
conditions (1.2 mM) and with the addition of 25 nM quinpirole.  Not only do these release 
profiles change dramatically with differenct calcium conditions, but also the facilitated 
release in B resembles the release profile in vivo under the same stimulation conditions. 
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The intrinsic fluorescence of dopaminergic neurons in GFP transgenic mice 
facilitates the placement of electrodes in brain slices.  This feature makes it possible to use 
remote stimulation in horizontal brain slices.  The use of remote stimulation to selectively 
excite dopamine neurons overcomes limitations in traditional brain slice experiments and 
expands the available experimental options.  Among these options is the ability to examine 
dopamine release dynamics in a manner consistent with in vivo protocols.   
While electrodes can simply be placed on fluorescent objects in the slice to elicit 
measurable catecholamine release, several criterion must be satisfied to ensure the 
selective stimulation of dopaminergic neurons.  The first criterion is to ensure that release is 
elicited by stimulating axons and not terminals local to the microelectrode.  To avoid the 
release of neuroactive substances from cells adjacent to dopamine terminals, the 
stimulating electrode must be separated a sufficient distance from the microelectrode to 
eliminate a stimulated response from the terminals.  An electrode separation of at least 600 
µm is sufficient to avoid stimulating dopamine terminals local to the microelectrode and by 
extension avoids the stimulation of other terminals and cell bodies in close proximity. A 
second criterion is to measure release selectively from dopaminergic neurons and not other 
neurons that release electroactive substances.  Many cell types have projections that 
traverse the MFB.  Therefore, stimulating axons in the MFB provides little selectively.  
Selectivity is provided by placing the microelectrode in locations where dopamine neurons 
terminate and other cell types projecting from the MFB do not.  The primary interferent from 
neurons known to traverse the MFB is norepinephrine.  Noradrenergic neurons might be 
expected to express GFP since TH is expressed in those cells; however noradrenergic cells 
simply do not fluoresce or fluoresce so weakly as to be undetectable (Kessler et al., 2003).  
This was confirmed by the immunohistochemical results of this work.  The lack of GFP 
expression in noradrenergic neurons may be due to where the transgene was inserted in the 
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chromosome.  For example, the transgene could be in the proximity of a cis regulatory unit, 
a segment of DNA that plays a role in determining the temporal and spatial domains of gene 
expression (Zheng et al., 2003).  The immunohistochemical results provide clear evidence 
of locations where dopaminergic neurons traversing the MFB terminate in regions free of 
noradrenergic terminals.  To confirm that these regions are free of noradrenergic terminals, 
NET uptake inhibitors were used.  It has been previously reported that desipramine has little 
effect on uptake in the nucleus accumbens and that the action of DAT provides uptake 
(Jones et al., 1995).  Since desipramine failed to change the rate of uptake but GBR-12909 
did, one can safely assume that the microelectrode was placed in locations where release is 
dominated by dopamine. 
Release in brain slices using local stimulation has been reported to respond 
differently to changes in stimulation parameters, such as pulse number and frequency, than 
release measured in vivo when stimulating the MFB (Kennedy et al., 1992a).  Since the 
MFB is being stimulated in these brain slice experiments, it may make the changes in 
release with changes in stimulation pulse number and frequency more similar to that 
observed in vivo.  While important differences still exist in the brain slice environment 
compared to the intact brain, the use of remote stimulation has altered the dopamine 
response in brain slices to these stimulation manipulations.  One reason may be a reduction 
in the number of terminals responding to the stimulation.  The concentrations of released 
dopamine are much lower with remote stimulation than local stimulation, presumably 
because fewer terminals are releasing dopamine.  The smaller magnitude responses with 
remote stimulation may allow the terminals to act within their dynamic range. 
The small diameter of the microelectrode provides the spatial resolution necessary to 
probe the heterogeneity of release sites within a brain slice.  Investigating this heterogeneity 
is more challenging with local stimulation since the magnitude of release is dependent on 
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the separation of the microelectrode from the stimulating electrode (Figure 5.3).  This can 
also be seen in Figure 5.9a, where the magnitude and temporal profile change with the 
lowering of the electrode into and through the brain slice. These changes in the signal 
underscore the impact of the distance between the microelectrode and the release sites.   
Several factors will impact the distance to sampled release sites.  First, the top layers 
of the brain slice are considered dysfunctional due to the cell damage from slicing.  Second, 
there has been shown to be an oxygen gradient through the slice (Kennedy et al., 1992b).  
This may be due to cells closer to the surface of the slice consuming oxygen from the buffer 
for respiration.  This would suggest that terminals at the lowest layers of the slice may not be 
releasing normally.  Third, the permeation of the stimulation pulse may limit the depth at 
which release is elicited.  Fourth, extracellular dopamine is quickly cleared by a high-affinity 
uptake system that will limit the distance released dopamine can diffuse.  These factors are 
relevant during remote stimulation.  The axons being stimulated presumably arborize into 
terminal fields from which the release is sampled.  Therefore detected release would be 
constrained to recording sites within a limited proximity to those terminal fields being 
stimulated via connected axons. 
Due to the way the slices were mounted in the slice chamber, the ventral surface of 
the horizontal slice is the surface identified at 0 µm depth.  As the electrode is lowered in the 
tissue, it is traversing from ventral regions of the brain in a dorsal direction towards the top of 
the brain.  The differences between samples in the depth at which the greatest release is 
measured may be attributable to the reproducibility of harvesting a brain slice from exactly 
the same location in the brain. The mesolimbic pathway is known to curve from ventral to 
dorsal as it approaches the Acb.  Some researchers tilt the brain when taking a horizontal 
slice to incorporate a greater number of whole neurons (Chuhma et al., 2004).   This bias 
would explain why release is larger in more dorsal recording sites.  Lateral heterogeneity is 
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also consistent with the known anatomy.  The distribution of release sites has a positive 
skew, meaning there are more release sites in a medial direction.  This corresponds with the 
direction of the pathway, as can be seen in the atlas image in Figure 5.5. 
There are a number of experiments that can now be attempted with the 
establishment of a remote stimulation protocol.  One can now explore poorly understood 
pathways such as the tuberoinfundibular pathway which consists of dopamine neurons in 
the hypothalamus that project to the pituatary gland.  Additionally, one can use sagittal 
slices to encompass the nigrostriatal pathway that curves dramatically dorsal from the 
substantia nigra (SN, posterior to the VTA) to the caudate putamen (CP) (Figure 5.1).  
Additionally, dopamine release dynamics can be probed.  The stimulation pulse number and 
frequency experiments show that the dopamine neurons respond differently to the same 
stimulations when stimulated remotely.  Investigating facilitation is just one factor that 
contributes to release dynamics and only the proof of concept has been illustrated here 
(Figure 5.12).  These processes should be investigated more fully.  In vitro experiments, 
such as in brain slices, allow more control to elucidate the underlying mechanisms. 
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Chapter 6 
Dopamine and Serotonin Measurement in Mixed Samples 
Introduction 
 Fast-scan cyclic voltammetry (FSCV) with carbon-fiber microelectrodes is a sensitive 
technique for the detection of serotonin and dopamine.  It also provides the spatial and 
temporal resolution necessary for measuring rapid changes in extracellular concentrations 
within mouse brain slices (Jones et al., 1999).  In this work, a method for determining 
serotonin and dopamine concentrations in a mixed solution and in various brain regions are 
discussed.   
 Serotonin is an important neuromodulator found throughout the brain.  It has 
been widely studied for its role in depression (Lemberger et al., 1985) and the sleep-wake 
cycle (Medanic and Gillette, 1992).  It also has been shown to overlap widely with the 
distribution of dopaminergic neurons (Lavoie and Parent, 1990; Corvaja et al., 1993; 
Moukhles et al., 1997) and these systems have been shown to interact (Hery et al., 1980; 
Nedergaard et al., 1988; Trent and Tepper, 1991; Cobb and Abercrombie, 2003).  The 
ventral tegmental area (VTA) and substantia nigra compacta (SNc) are regions containing 
dopaminergic cell bodies.  The VTA sends out the primary projections of the mesolimbic 
pathway involved in reward based learning (Schultz et al., 1997) and drug addiction (Di 
Chiara and Imperato, 1988; Wise, 2004).  Moreover, serotonin reduces dopaminergic cell 
firing in the VTA (Liu et al., 2003).  The SNc is part of the nigrostriatal dopamine pathway 
that is involved in motor movement (Bradbury et al., 1985; Missale et al., 1998; Sealfon, 
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2000) and Parkinson’s disease (Bjorklund and Lindvall, 1984), yet serotonin is the primary 
neuromodulator present in the region (Bunin et al., 1998).   
The mesolimbic dopamine pathway has been linked to the red nucleus (RN) (Bosler 
et al., 1983) and the interstitial medial longitudinal fasciculus (iMLF), a thalamic region 
(Toonen et al., 1998).  The role of serotonin and dopamine in these regions has been little 
study, but the function of these regions indicates a role. The RN is involved in the sleep-
wake cycle (Licata et al., 2001), a process known to involve serotonin, and the iMLF has 
been implicated in Parkinson’s disease (Racette et al., 2004), which involves the loss of 
dopaminergic neurons.   
Electrochemical measurements and immunohistochemical labeling have been 
conducted to determine the relative levels of serotonin and dopamine in the VTA, SNc, RN, 
and iMLF (anatomical locations1 shown in Figure 6.3).  Since these regions are present in 
the same coronal brain slice, they can be probed within the same preparation.  GFP 
transgenic mice express green fluorescent protein (GFP) in their dopaminergic neurons 
(Kessler et al., 2003).  These mice are used because their dopaminergic cells can be easily 
identified.  Their intrinsic fluorescence aides in electrode placement for small, sparsely 
innervated regions, such as the iMLF, and for finding the RN, a non-dopaminergic region, 
that is adjacent to fluorescent regions. 
 
Materials and Methods 
Chemicals 
Bupropion hydrochloride and Citalopram hydrobromide were obtained from Sigma-Aldrich 
(St Louis, MO, USA). 10 mM stock solutions were prepared by dissolving the appropriate 
weight of drug into a known volume of deionized water. 
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Animals 
Animals were handled in accordance with protocols approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina. A transgenic mouse line in 
which catecholamine containing cells express the gene for the enhanced green fluorescent 
protein was used (Kessler et al., 2003).  Male Sprague-Dawley rats (225-350g; Charles 
River, Wilmington, MA, USA) were also used.  Upon receipt, mice and rats were housed at 
the University of North Carolina Animal Husbandry Facility in Kerr Hall. Mice and rats were 
provided food and water ad libitum and were kept under conditions of controlled 
temperature, humidity, and a 12-h light/dark cycle. 
Brain slices 
Mice were deeply anesthetized by ether inhalation and decapitated.  The brain was 
immediately removed and placed in ice-cold aCSF.  The aCSF solution consisted of (in 
mM): NaCl 126, KCl 2.5, NaH2PO4 1.2, CaCl2 2.4, MgCl2 1.2, NaHCO3 25, HEPES 20, D-
glucose 11. The pH was adjusted to 7.4 with 5 M NaOH and the buffer was continuously 
saturated with 95% O2/5% CO2. The cerebellum was sliced off with a razor blade and the 
brain was mounted on a Teflon block using Krazy Glue ®. Brain slices were made using an 
NVSL vibratome (World Precision Instruments, Sarasota, FL, USA). Coronal slices 
containing the midbrain were made 300-µm thick, obtained at -2.8 to -3.3 mm from bregma.  
For immunohistochemistry, the brain slices were made 200-µm thick.  Brain slices were 
stored in ice-cold aCSF. A single slice was submerged under aCSF maintained at 34°C and 
continuously flowing (2 mL/min) through a superfusion chamber (Warner Instruments, 
Hamden, CT, USA).  Each brain slice was equilibrated for 30 min prior to obtaining 
measurements.  When pharmacological agents were used, they were added to the buffer to 
a known concentration and superfused for 30 min prior to measuring their effect.  
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Rats were used for immunohistochemical experiments. They were sacrificed with 
urethane (1.5 g/kg, i.p.) and perfusd intracardially with 80 mL 0.9% saline followed by 80 mL 
of 4% paraformaldehyde.  The brain was extracted and sliced as described above for mice.   
Electrochemistry 
Carbon-fiber cylinder microelectrodes were made as previously described (Kawagoe et al., 
1993) using T650 carbon fibers (Amoco, Greenville, SC, USA) cut to a length of 25 µm.  
Electrodes were epoxied (Miller-Stevenson, Danbury, CT, USA) to ensure a good seal, and 
dipped immediately in acetone for a few seconds to remove residual epoxy from the carbon 
fiber.  A triangular waveform, starting at -0.4 V, increasing to 1.0 V, and scanning back to -
0.4 V, was applied to the carbon-fiber working electrode, versus a Ag/AgCl reference 
electrode, at a scan rate of 600 V/s.  This will be referred to as the normal waveform.  A 
second, serotonin-selective waveform was used, and this will be referred to as the modified 
waveform.   The waveform was used as described previously (Bunin et al., 1998).  It 
consists of scanning from +0.2 V to 1.0 V, down to -0.2 V and back up to 0.2 V at 1000 V/s.  
An update rate of 10 Hz was used for all experiments.  The sensitivity of the waveforms to 
dopamine and serotonin were tested with flow injection analysis (FIA) 
The carbon fiber was inserted until the tip was 60-70 µm below the surface of the 
brain slice between the prongs of a bipolar stimulating electrode (FHC, Bowdoinham, ME, 
USA), situated 200 µm apart. To evoke release, a biphasic stimulating current pulse (2 ms 
each phase, 350 µA in amplitude) was applied to the stimulating electrode. The current 
arising from dopamine and serotonin oxidation (at about 0.6 V) in successive 
voltammograms was measured and plotted versus time.  This current was converted to 
concentration with post-calibrations.  
Immunohistochemistry 
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Slices were fixed in 2% formaldehyde in Sorenson's buffer (0.15 m Na2HPO4/KH2PO4 at pH 
7.4) for 4 h. The slices were rinsed three times with 1X PBS (Tissue Culture Facility, Chapel 
Hill, NC, USA). Then, normal goat serum (NGS, Life Technologies, Rockville, MD, USA) was 
combined with 0.2% BSA/PBS solution (1 : 10, NGS : BSA/ PBS) containing 0.3% Triton-
100X.  The slices were incubated in this blocking solution for 2 h.  The primary antibody 
solutions were incubated for overnight (15hours) at 4°C with slow agitation and rinsed with 
PBS.  For co-localization experiments, secondary antibody was diluted 1:1000 and 
incubated overnight with the slices.  A primary antibody for TH (Goat, Invitrogen), diluted 
1:400, was used with a goat anti-rabbit secondary antibody (Invitrogen) conjugated to Alexa 
Fluor ® 555.  For TPH/GFP double labeling experiments, primary antibodies were diluted 
into 0.5 mL of PBS and then 5 mL of blocking solution to final dilutions as follows: anti-GFP 
(Sheep, Invitrogen), 1:200; anti-TPH (Rabbit, Invitrogen), 1:200.  The secondary antibodies 
used were donkey anti-sheep conjugated to Alexa Fluor ® 555 and Donkey anti-rabbit 
conjugated to FITC. Then, the slices were rinsed with PBS, placed on slides, and examined 
by confocal microscopy. 
Confocal microscopy 
Throughout this work, anatomical locations were determined by comparison with a mouse 
brain atlas (Paxinos and Franklin, 2004). The brain slices containing the desired regions 
were placed onto microscope slides with glass wells to maintain their structural integrity. Into 
these wells, Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA) was added. After the 
slices were placed in mounting medium, they were coverslipped, and sealed with clear nail 
varnish.  The confocal images were collected on a Leica SP2 Laser Scanning Confocal 
Microscope (Leica Microsystems, Confocal Microscopy, Germany) in the Michael Hooker 
Microscopy Facility at the University of North Carolina at Chapel Hill.  Photomultiplier tubes 
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were used to detect the fluorescence from the fluorochromes in the multiple-labeling 
experiments. 
Epifluorescent Microscopy 
To visualize the fluorescence in brain slices, an upright microscope (Nikon Eclipse E600FN, 
Melville, NY) was used with a xenon lamp source to excite fluorescence.  a Nikon endow 
GFP bandpass filter set (filter 470 CWL for excitation, 525 CWL for emission, and a 495 LP 
dichroic mirror) was employed when viewing samples from GFP mice.  A CCD camera 
(Photometrics Sensys, Tucson, Arizona) was used to capture images.   
 
Results 
Flow Injection Analysis (FIA) 
The normal waveform is sensitive to dopamine and more sensitive to serotonin (Figure 6.1).  
However with this waveform serotonin quickly fouls the electrode, decreasing its sensitivity 
(data not shown).  The modified waveform prevents this fouling and provides selectivity over 
dopamine.  In fact, 1 µM dopamine is undetectable (Figure 6.1).  Figure 2 shows that the 
oxidative current for serotonin and dopamine are additive in a mixed solution.  The current at 
0.6 V for a 1 µM dopamine solution and a 1 µM serotonin solution, when added together, 
equal the current at 0.6 V for a solution containing both 1 µM dopamine and 1 µM serotonin 
(Figure 6.2b, ratio = 1.05 +0.05).   
This additive property allows the use of both waveforms in a mixed solution to 
determine the concentration of each analyte.  The modified waveform can be used to  
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Figure 6.1.  Differntial response of DA and 5-HT in a flow cell measured with two different 
waveforms.  The CV’s for 5-HT are across the top and the CV’s for an equal concentration 
of DA is shown below.  The modified waveform is insensitive to a 1µM dopamine solution. 
 
 
 
 
Normal Waveform Modified Waveform
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Figure 6.2.  FIA of DA and 5-HT comparing their cyclic voltammograms when alone and 
when mixed.  A.) CV’s of a 1µM dopamine and a 1 µM serotonin solution are overlayed with 
the CV of a mixed solution of 1µM dopamine and 1 µM serotonin.  B.)  The current at 0.6 V 
for 1µM dopamine and a 1 µM serotonin solution are normalized to that of a mixed solution 
of both.  DA + 5-HT is the result of adding the current from the individual solutions and 
normalizing it to the mixed solution.  These results are essentially identical (1.05 +0.05). 
A 
B 
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determine the serotonin concentration.  Knowing the sensitivity of the electrode to serotonin 
with the normal waveform and the concentration of serotonin, one can find the current 
contribution of serotonin with the normal waveform.  Then, the oxidative current from 
dopamine can be determined and be used to determine the dopamine concentration. 
Immunohistochemistry 
Tyrosine hydroxylase (TH) was used as a marker for dopaminergic neurons in rat brain 
slices.  Adjacent confocal bright field and fluorescent images correspond to the same 
location in a brain slice.  The oval on the bright field image indicates the area of interest.  
Figure 6.4a indicates the iMLF and shows the presence of TH.  Figure 6.4b indicates the 
position of the RN which does not label for TH but whose ventral border is outlined by the 
heavy labeling of the VTA. 
 In GFP transgenic mice GFP expression is driven by the promoter for TH, the rate-
limiting enzyme in catecholamine synthesis and is used as a marker for dopaminergic 
neurons.  Tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin synthesis, 
was used as a marker for serotonergic neurons.  In Figure 6.5a, the SNr is heavily labeled 
for TPH.  In contrast, the SNc is labeled for both TPH and GFP.  The VTA is labeled for both 
TPH and GFP as well.  In fact, the labeling of TPH can be seen in GFP positive cells. 
Serotonin and Dopamine in the Midbrain 
The concentration of stimulated (20-pulse, 60Hz) serotonin and dopamine release were 
measured in the VTA, RN, and iMLF in brain slices from GFP transgenic mice.  The 
determination of concentration was executed using the procedure described above with the 
normal and modified waveforms.  The current traces at 0.6 V is shown for all three regions  
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Figure 6.3.  Identified target regions (yellow squares and oval).  Labeled mouse brain 
(mbl.org) on the right, and a mouse brain atlas (braininfo.rprc.washington.edu) showing the 
regions diagrammatically on the left.  Note the panels are mirror images because they are 
taken from opposite sides of the brain.  The brain is generally symmetrical about the midline. 
 
 
 
 
 
121 
 
 
 
 
 
 
Figure 6.4.  TH (cyan) labeling in the midbrain. Confocal fluorescent and bright field images 
of the A.) iMLF and B.) RN, identified in the ovals encapsulating the region.  Adjacent 
images are from the same slice and location.  
 
iMLF 
RN 
VTA 
RN 
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Figure 6.5.  GFP and TPH co-localization determined with confocal microscopy. Immuno-
histochemical labeling of TPH (yellow) and GFP (cyan) in the A.) SN and B.) VTA.  At the 
right is a mouse brain atlas indicating the location of these areas in a brain slice. 
SN
A 
B 
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using both waveforms (Figure 6.6a).  The cyclic voltammograms (CV) for each waveform 
taken at the peak of release are shown below the trace for the corresponding region (Figure 
6.6b).   Stimulated release is largest in the VTA, followed by the iMLF, then the RN.  The 
difference in magnitude of release measured by the two waveforms is largest in the VTA 
and the normal waveform CV looks the most like dopamine.  There is very little difference in 
the traces in the RN using either waveform, and the CV’s confirm that release is mostly 
serotonergic.  The results across five mice are displayed in Figure 6.6c.  They show that 
dopamine release is largest in the VTA and serotonin release is largest in the iMLF.  There 
is three times as much serotonin as dopamine in the RN. Interestingly, there is some small 
amount of dopamine release measured in the RN despite the weak TH labeling. 
Fluorescence and Release in the SNc 
Cells expressing GFP can be indentified in the SNc and an oxidation current at 0.6 V is 
generated upon a 10-pulse, 60 Hz stimulation (Figure 6.7). However, there is no relationship 
between the fluorescence intensity and current (Figure 6.7c, r2 = 0.001).  To determine if the 
release measured is dopaminergic or serotonergic, the serotonin selective modified 
waveform was used at each position.  From the CV’s in Figure 6.7b, one can see that 
serotonin is being measured (CV from position 2 shown as an example).  Moreover, the 
current observed decreases from positions ventral to dorsal (Figure 6.7e).  The most ventral 
position, 2, is nearest the SNr, a region that labeled heavily for TPH.  The labeling of the 
SNc in Figure 6.5a reveals that the dopaminergic cells are surrounded by serotonergic 
terminals.   Across all positions the serotonin concentration measured in this slice is 237 +2 
nM.  In fact, serotonin constitutes 72 +4% of the signal measured with the normal waveform. 
Remote Stimulation of the VTA 
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Figure 6.6. Dopamine and serotonin release in the midbrain. A.)Total current traces at 0.6 V 
for each waveform in the same location across three regions.  B.) The corresponding CV’s 
are below the traces.  CV’s recorded using the normal waveform are in the first row and 
those using the modified waveform are below them in the second row. C.) A summary of 
dopamine and serotonin concentrations measured across all three regions for n = 5 mice.  
A 
B 
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Figure 6.7.  SNc relationship between fluorescent intensity and dopamine release. A) 
Epifluorescent image of a GFP mouse brain slice containing the SNc. Squares indicate 
electrode location for the corresponding traces. B) Stimulated release (20-pulse, 60 Hz) at 
the corresponding positions.  The orange squares indicate the end of the stimulation. C)  
Based on electrode sensitivity for serotonin with two different waveforms, the released 
analyte is 72 +4% serotonin or 237 +2 nM across all positions. D.)  The linear regression of 
the relative fluorescence in the squares compared to the release at those positions (r2 = 
0.001). Release magnitude is more tightly associated with proximity to the SNr, the black to 
the left (ventral) in the image. 
 
A B
C 
D 
126 
 
Stimulating the MFB caused the release of electroactive substances in the VTA (Figure 6.8).  
The released substance was electrochemically identified as serotonin (Figure 6.8c).  This 
was confirmed with pharmacology.  Bupropion (bpr) is a selective inhibitor of the dopamine 
transporter (DAT).  Addition of 500 nM bpr did not alter the magnitude or time course of the 
signal.  However 500 nM citalopram, a selective inhibitor of the serotonin transporter 
(SERT), increased the magnitude of the signal and eliminated uptake.  The uptake was very 
weak in the control file and did not change with the addition of bpr.  The trace remains 
constant after stimulation in the presence of citalopram, indicating that uptake is absent.  
The magnitude of the signal is greater when uptake is absent because extracellular 
serotonin is not cleared between stimulation pulses. 
 
Discussion 
Using the normal waveform and the serotonin-selective modified waveform, the 
concentrations of dopamine and serotonin can be determined for a mixed solution.  The 
modified waveform is relatively insensitive to dopamine and can therefore be used to 
determine the concentration of serotonin.  Knowing the concentration of serotonin allows the 
dopaminergic concentration to be calculated.   The ability to determine the concentrations of 
dopamine and serotonin in a mixed solution has been exploited in regions of the rodent 
brain that contain both neuromodulators.   The VTA is considered a dopaminergic cell body 
region and serotonin has not been previously detected in this region electrochemically 
(Cragg et al., 1997; John et al., 2006).  The presence of a serotonin receptor (5-HT2C) in the 
VTA has been reported with immunohistochemical experiments (Bubar and Cunningham, 
2007) and the protein for 5-HT2C has been detected in the VTA  
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Figure 6.8.  Remote stimulation of the VTA. A.) A representation of the region from the rat 
brain atlas (Paxinos and Watson, 2007) and an epifluorescent image showing electrode 
placement. B.)  Traces recorded pre-drug (aCSF), with the addition of 500 nM Bupropion, 
and 500 nM Citalopram in the presence of 500nM Bupropion.  C.)  CV’s recorded at the 
peak of release pre-drug and post-Citalopram.  These CV’s identify the analyte as serotonin. 
 Acb VTA
MFB 
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(Abramowski et al., 1995; Clemett et al., 2000).  The presence of a receptor demands an 
endogenous ligand to bind and activate it.  The waveform used most recently by Jones and 
coworkers distinguishes between dopamine and serotonin by the potential of the reduction 
peaks for each analyte (Jones et al., 1996).  Theyreport that release in the VTA is 
exclusively dopaminergic.  The modified waveform used here is more sensitive to serotonin 
because the oxidation peak is measured and dopamine interference is eliminated.  
However, release is mostly dopaminergic, but it does contain a serotonin component 
(approximately 33% of the total current with the normal waveform, Figure 6.6c). 
Although the iMLF labeled for TH, the majority of the electrochemical signal is 
serotonin.  In cats, serotonergic neurons from the median raphe nucleus (MRN) extend to 
the iMLF (Jacobs and Azmitia, 1992).  Serotonin suppression of cholinergic burst firing 
regulates rapid eye movement (REM) during sleep in rats, (Luebke et al., 1992) and it is 
these saccadic movements that become impaired in Parkinson’s disease for some humans 
(Mosimann et al., 2005).   Lesions of the iMLF in monkeys leads to loss of all rapid eye 
movements (Henn et al., 1989). This is a region that has not been study previously with 
electrochemistry.  However, electrochemistry with microelectrodes could elucidate the 
connection between the iMLF, the dopamine systems, and symptoms of Parkinson’s 
disease. 
The modified waveform has been used by our lab previously to measure serotonin in 
the SNc and the dorsal raphe (DR), which are known serotonergic regions (Bunin et al., 
1998).  Our measurements in the SNc confirm the earlier work and add the presence of a 
small concentration of stimulated dopamine release.  Using only one waveform, the 
dopaminergic currents would go unidentified since the majority of the current arises from 
serotonin oxidation.  Those results have been extended by measuring serotonin and 
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dopamine in the RN, another known serotonergic region.  This region also releases small 
concentrations of dopamine, which has not been reported previously.   
The small concentrations of dopamine in these regions could possibly be attributed 
in error.  If the concentration of serotonin being released and measured changed between 
the applications of the different waveforms, then the current considered due to serotonin 
would be wrong, and thus, the difference in current would be assigned to dopamine 
oxidation in error.  Additionally, the strength of the method is dependent on the quality of the 
calibrations using the two waveforms.  If one of the three calibrations is inaccurate, then the 
determination of one or both of the analytes would be in error as well.  Nevertheless, 
serotonin has definitively been measured electrochemically in regions heretofore 
unreported.   
 GFP transgenic mice have been used throughout these experiments to facilitate 
electrode placement.  The intrinsic fluorescence of dopaminergic neurons aids in 
determining the location of the target structure.  Moreover, these mice can be used to do 
novel experiments involving remote stimulation of release measured in the VTA.  Initially our 
hypothesis was that antidromic stimulation, action potentials propagating towards the cell 
bodies, would cause dopamine release from cell bodies in the VTA.  However the results 
here indicate that serotonin is being released from terminals.  The modified waveform 
measures a CV indicative of serotonin, and citalopram inhibits uptake.  Serotonergic axons 
are heavily labeled within the MFB (Azmitia and Gannon, 1983).  We hypothesize that axons 
within the MFB are being stimulated and are releasing the serotonin being detected. 
 The use of FSCV with multiple waveforms applied to a carbon-fiber microelectrode is 
a powerful technique for measuring multiple analytes in a mixed environment, such as exists 
in many areas of the brain.  Moreover, the modified waveform is sensitive to small 
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concentrations of serotonin and was used to detect serotonin in regions where it had not 
been previously reported.  These electrochemical approaches can be used to probe novel 
regions, such as the iMLF and RN, and novel contexts, such as remotely stimulating the 
VTA. 
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